CORONA Main Coronavirus thread

Heliobas Disciple

TB Fanatic
(fair use applies)


Combined anti-seizure drug and omega-3 may lower COVID-19 risks
by Claire Kowalick, University of Texas Health Science Center at San Antonio
September 9, 2024


urologist-discovers-th.jpg

Valproic acid use is associated with diminished risk of contracting COVID-19, and diminished disease severity: Epidemiologic and in vitro analysis reveal mechanistic insights. Credit: PLOS ONE (2024). DOI: 10.1371/journal.pone.0307154

Ronald Rodriguez, MD, Ph.D., professor of medical education and urology at Joe R. and Teresa Lozano Long School of Medicine at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), has discovered that the combination of valproic acid and docosahexaenoic acid (DHA) may reduce the risk of contracting COVID-19 and lessen its severity, according to a study published in August.

The research appears in the journal PLOS ONE.

Valproic acid is a common anti-seizure medication, and DHA is a type of omega-3 fatty acid known to improve brain and heart health.

When the COVID-19 pandemic began in 2020, Rodriguez received a kidney transplant, raising his own concerns about being at high risk for infection and its complications. Rather than sitting back at home, the urologist shifted his focus and investigated potential treatments for COVID-19. Rodriguez drew from his background in virology and gene therapy and explored an effective and accessible solution to fighting the virus.

Rodriguez's previous adenoviral gene therapy research in prostate cancer had led him to explore the antiviral potential of valproic acid. Approved by the U.S. Food and Drug Administration, valproic acid showed promise in preventing the COVID virus from replicating, but initial doses proved potentially toxic.

"A combination of a nutritional supplement and an anti-seizure drug in the right ratios with the right timing could be very profound in inhibiting the development of and replication of COVID and more importantly, because of the way it works, there are a couple of thousand genes that are affected," Rodriguez said.

A review of electronic medical records data from more than 3 million patients showed those taking valproic acid were less likely to develop COVID-19, and those patients who tested positive for COVID-19 were less likely to be admitted to the emergency room, inpatient hospital and intensive care unit (ICU).

"Valproic acid in combination with DHA strongly activates ancient antiviral pathways against large classes of viruses in the cells that are usually repressed by viruses, like coronaviruses. When they get in, the first thing they do is repress many of these antiviral pathways. This combination drug overcomes that and then turns it on to a strong extent and those ancient pathways are able to rid themselves of the virus," Rodriguez said.

Rodriguez and his research team envision usage of the valproic acid combo as a short-term, preventive treatment to avoid getting COVID-19 or to lessen its severity, like how a Z-Pak, a short course of azithromycin, diminishes a bacterial infection.

For older adults, people who have health issues or those who are immunocompromised, this discovery could allow them to return to their normal routine and experience things they have not been able to since COVID began.

Rodriguez sees the study's results as an opportunity for the development of low-cost alternatives for treatment around the world where other medications are not available.

More information: Amanda Watson et al, Valproic acid use is associated with diminished risk of contracting COVID-19, and diminished disease severity: Epidemiologic and in vitro analysis reveal mechanistic insights, PLOS ONE (2024). DOI: 10.1371/journal.pone.0307154
Journal information: PLoS ONE
Provided by University of Texas Health Science Center at San Antonio
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Mysterious respiratory illness outbreak in Gujarat, India kills 13 in last 3 days
Nikhil Prasad Fact checked by:Thailand Medical News Team
Sep 10, 2024

A new and mysterious respiratory illness is sweeping across Gujarat, India, leaving the state on high alert. In just three days, 13 lives have been lost, with hundreds more potentially infected as healthcare workers scramble to understand the cause of the outbreak. The situation has escalated rapidly, raising alarms both within India and globally.


Alarming Symptoms and Rapid Progression
Healthcare facilities in Gujarat have reported a sudden surge in cases of a strange respiratory illness that leads to swift deterioration in patients' health. What begins as mild symptoms like fever, cough, sore throat, and runny nose soon spirals into more severe conditions. Many patients experience debilitating body aches and breathing difficulties, often requiring immediate hospitalization.

Doctors report that as the disease progresses, pneumonia frequently develops, and many patients are placed in intensive care units (ICUs). Particularly concerning is the emergence of secondary lung infections caused by the Pseudomonas bacteria in the most severe cases. While this bacterium contributes to complications, it is not believed to be the primary cause of the illness. The initial pathogen responsible for triggering these severe symptoms remains elusive, leaving healthcare workers searching for answers.


Children Among the Victims
Tragically, among the 13 who have died from this illness are four children under the age of 12. This has further intensified concerns, as young children are often seen as particularly vulnerable during infectious outbreaks. Authorities and health experts fear that the death toll could rise further if the source of the illness remains unidentified and untreated.


Hundreds Hospitalized, Critical Cases Continue to Mount
While official figures remain uncertain, it is believed that hundreds more people across Gujarat may already be infected. Hospitals are reportedly overwhelmed, with many patients requiring supplemental oxygen therapy and intensive care. Healthcare facilities are under strain as they struggle to manage the influx of critical cases, further complicating efforts to contain the outbreak.

So far, tests for common respiratory pathogens such as Influenza viruses, COVID-19, Respiratory Syncytial Virus (RSV), and the lesser-known Chandipura virus have all returned negative results. Even tests for other endemic diseases like Dengue fever have failed to yield any clues. With the mystery deepening, medical professionals remain baffled by this unknown pathogen, which appears resistant to current diagnostic approaches.


Government and International Response
The state government has taken swift action to address the growing crisis. Health teams from various parts of India have been mobilized to provide assistance in Gujarat, and the World Health Organization (WHO) has been notified of the emerging outbreak. The involvement of global health authorities highlights the seriousness of the situation, as efforts are ramped up to identify the pathogen and develop treatment protocols.

In response to the outbreak, public health measures are being intensified across Gujarat. Hospitals are on high alert, and authorities are urging residents to take preventive measures, such as wearing masks, avoiding crowded places, and seeking medical attention if they experience any respiratory symptoms. The speed at which the illness spreads and its severity make containment a top priority.


Media Coverage and Public Anxiety
Local and national news outlets as well as Medical News outlets in India have yet to report on this crisis unfolding in Gujerat as health and government officials have been trying to conceal the developing crisis.

The Wion news outlet was the only media to first to break the story of the developing health crisis in Gujerat.


The lack of information about the cause of the outbreak and the speed at which it is spreading has fueled concerns, with many residents fearful of further escalation.

The situation remains fluid, and doctors, researchers and health officials are working around the clock to understand the illness and implement measures to protect the public. With the origin and nature of the disease still unknown, the people of Gujarat are left waiting for answers and hoping for a swift resolution to the crisis.
 

Zoner

Veteran Member
Here is a response to Dr. Campbell’s YouTube on nano technology in the vaccines.


The origins of the nanotechnology narrative.​

Repetitive messaging is the only technology ever needed for mind control. Seductive sci-fi narratives are a particularly insidious version of this "technology".​


SASHA LATYPOVA
SEP 10, 2024
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Cuomo defends COVID-19 nursing home decisions in combative House committee hearing

Michael Hill - AP
Updated Tue, September 10, 2024, 7:02 PM EDT

Former New York Gov. Andrew Cuomo faced blistering criticism in an often combative congressional subcommittee hearing Tuesday over his handling of the COVID-19 pandemic during the time when the virus was spreading through nursing homes.

Republicans who questioned the Democrat zeroed in on a controversial directive his administration issued in March of 2020 that initially barred nursing homes from refusing to accept patients just because they’d had COVID-19. More than 9,000 recovering coronavirus patients were released from hospitals into nursing homes under the directive, which was rescinded amid speculation that it had accelerated outbreaks.

U.S. Rep. Elise Stefanik of New York called the directive “deadly.” Rep. Brad Wenstrup, the Ohio Republican who chairs the House Select Subcommittee on the Coronavirus Pandemic, said it was inconsistent with federal guidance and its consequences were “dangerous and disastrous.” Republicans accused Cuomo of staging a cover-up to hide mistakes that endangered nursing home residents.

“Governor, you own this. It’s your name on the letterhead. This is your directive, whether you knew about it or not," Wenstrup said. “You’re the leader. The buck stops with you, or at least it should."

In over two hours of testimony, Cuomo adamantly defended his actions and blamed the former Trump administration for failing to provide enough testing and personal protective equipment in the early days of the pandemic.

“These are all diversions to blame New York and other states for the culpability of the federal response, which was malpractice,” Cuomo said.

The testimony is unlikely settle disputes over the nursing home order, which was issued to keep hospitals from becoming overwhelmed with COVID-19 patients who were no longer sick enough to require hospitalization but needed nursing home care for other conditions and couldn’t simply be discharged or sent home.

A report issued by the House committee didn't delve into the question of whether significant numbers of people discharged from hospitals were still contagious with the virus when they were readmitted to nursing homes, or whether they then passed the virus to other patients.

Some public health experts have said it is likely that most of the people who died in New York nursing homes during the early months of the pandemic got it from staff, from visiting loved ones, or from fellow patients who hadn't yet been hospitalized.

Cuomo told the panel that its report provided no evidence to support the allegation that the directive helped spread the virus.

“In fact, the report finds no causality whatsoever. Not one death,” he said.

In a particularly heated exchange, Stefanik asked Cuomo if he was negotiating a book deal as people in nursing homes were dying. They each accused each other of making up facts before Stefanik demanded Cuomo apologize to families who lost loved ones.

“There are families sitting here. I want you to turn around, look them in the eye and apologize, which you have failed to do," she said. "Will you do it?”

“This is not about political theater,” Cuomo responded.

The congressional committee said it had also determined that Cuomo and his top aides tried to deflect any potential blame by ordering up an unscientific report concluding that the rescinded March directive likely had little impact on fatalities.

There were about 15,000 COVID-19 deaths among long-term care residents in New York, far more than the initial number disclosed. Cuomo said some figures were initially withheld out of concerns about accuracy.

“The governor was desperate to change the narrative — to dispel of the notion that his administration failed nursing home residents,” said Republican Rep. James Comer, who chairs the House Oversight Committee.

Cuomo resigned from office in August 2021 amid sexual harassment allegations, which he denies.

Cuomo was widely seen as a reassuring figure in the early months of the pandemic, but his reputation suffered after revelations that his administration released an incomplete accounting of the number of deaths at nursing homes and assisted living facilities.

Cuomo testified before the subcommittee in June , but it was behind closed doors. Top former Cuomo administration officials also were interviewed as part of the investigation.

A separate state report commissioned by Cuomo's successor, Gov. Kathy Hochul, and released this summer found that while the policies on how nursing homes should handle COVID-19 were “rushed and uncoordinated,” they were based on the best understanding of the science at the time.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Scientists discover dual roles of antibodies in COVID-19 infections
by University of Minnesota Medical School
September 10, 2024


scientists-discover-du.jpg

Dual-role epitope on SARS-CoV-2 spike enhances and neutralizes viral entry across different variants. Credit: PLOS Pathogens (2024). DOI: 10.1371/journal.ppat.1012493

Scientists at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have made a surprising discovery: antibodies can have opposite effects on viral infections in human cells.

The spike protein of SARS-CoV-2, the virus that causes COVID-19, enables the virus to enter human cells and is the primary target for the body's antibodies. Previous research has shown that antibodies can either block the virus, have no effect, or, in rare cases, assist the virus in infecting cells. While antibody drugs work to block infections, this new study challenges current understanding of their mechanisms.

Published in the journal PLOS Pathogens, this study is the first to identify an antibody that can both assist and block the virus. This particular antibody helps pre-omicron variants of the virus infect cells while preventing the omicron variant from doing the same. The study also explains how the antibody aids the pre-omicron virus in invading cells while blocking the omicron virus from succeeding.

The research team, led by Dr. Fang Li, co-director of the Midwest AViDD Center and a professor and endowed chair at the Medical School, along with Dr. Bin Liu, an associate professor at the Hormel Institute, research scientist Dr. Gang Ye, and graduate student Fan Bu from the Department of Pharmacology, made this surprising discovery.

"The battle between viral infection and treatment development is like an arms race. Our findings highlight how complex it can be to develop treatments as viruses evolve," said Dr. Li. "But it's important to note that the virus-boosting effect of this antibody was only observed in lab-grown cells, and there's no evidence it occurs in people."

At the Midwest AViDD Center, the team has been developing nanobodies—tiny antibodies from animals like llamas and camels—as treatments against viruses. These small antibodies are also excellent tools for studying how the SARS-CoV-2 spike protein works, which led to this unexpected discovery.

More information: Gang Ye et al, Dual-role epitope on SARS-CoV-2 spike enhances and neutralizes viral entry across different variants, PLOS Pathogens (2024). DOI: 10.1371/journal.ppat.1012493
Journal information: PLoS Pathogens
Provided by University of Minnesota Medical School
 

Heliobas Disciple

TB Fanatic
(fair use applies)


So THAT'S Why You Feel Like Crap After Your COVID Or Flu Shot
Julia Ries - Huffpost
Wed, September 11, 2024, 3:00 AM EDT

A new COVID-19 shot is here, and the Food and Drug Administration is recommending everyone 6 months old and up get it. Infectious disease experts have said the new vaccines, which target the KP.2 variant that’s behind the most recent wave of infections, do a better job at preventing serious outcomes like hospitalization and death.

If it’s been a second since you’ve gotten a booster shot, then let this serve as a quick reminder that it’s very normal — and common — to feel under the weather for a day or two after you get vaccinated, and flu-like symptoms are a sign the shot is doing its job.

“These symptoms may be reflective of a more robust immune response to the vaccine, which leads to longer-lasting and stronger protection,” Dr. Scott Roberts, a Yale Medicine infectious disease specialist, told HuffPost.


Here’s why you may not feel so well after getting the new COVID-19 vaccine.

According to the FDA, the new shots are expected to trigger side effects similar to those of the previous COVID-19 vaccines: headaches, fatigue, mild fevers and muscle pains.

Pain at the injection site is frequently reported, as is a red, itchy rash, which has been nicknamed “COVID arm.” Some individuals may also experience gastrointestinal issues, like diarrhea and nausea, as well as swollen lymph nodes.

The vaccine essentially tricks the body into responding as if you have an infection. As a result, “the side effects of the vaccine or booster can feel like a milder version of a COVID or flu infection when the immune system is stimulated, even though there is no actual infection happening,” Dr. Anne Liu, an infectious disease and allergy/immunology specialist with Stanford Medicine, told HuffPost.

The side effects vary from person to person, according to Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security and an infectious disease expert. And if you recently had COVID-19? Well, you might have a stronger reaction since your immune system was recently primed to go after the coronavirus, Adalja said.


Don’t worry, most side effects are a sign the vaccine is working.

When the immune system is stimulated, as it is when you’re vaccinated, it releases various molecules that trigger symptoms like muscle aches, Adalja said.

These side effects indicate the vaccine is doing its job. One study found that the more post-vaccine side effects you have, the stronger your immune response is. The study also found that experiencing chills, tiredness and headaches after getting one of the COVID-19 vaccines was linked to higher levels of neutralizing antibodies up to six months later.

With that said, many people don’t experience any symptoms after getting vaccinated — and that’s OK, too.

“Most people have minimal side effects to the COVID vaccination, but almost all of them form excellent memory responses to the vaccination,” Liu said.

Adverse events are uncommon, but they do happen. If you experience chest pain, shortness of breath or an irregular heartbeat, you should seek medical treatment immediately. These symptoms could be due to serious cardiovascular complications, like myocarditis or pericarditis.

“These are very rare, and in almost all cases the benefits of the vaccine outweigh the risk of these side effects,” Roberts said.


Will the side effects be worse if you get the flu and COVID-19 shots together?


If you want to knock out your COVID-19 and flu shots at the same time, go ahead. The Centers for Disease Control and Prevention confirmed it’s safe and effective, but don’t be alarmed if you feel extra crummy after.

According to the CDC, you’re more likely to experience these common side effects — fatigue, headaches and muscle aches — if you get the two shots together. Fortunately, these side effects are typically mild and should clear up within a few days.

“Most people tolerate getting the COVID booster and the flu shot at the same time with no or only mild side effects,” Liu said.


Is there anything you can do to reduce the side effects?


The best thing you can do, according to the CDC, is get some rest. Data has suggested that laying low after the shot boosts your immune response and helps your body restore and repair itself.

If your arm’s sore or itchy, apply an ice pack and try to move it up and down throughout the day. You’ll also want to drink plenty of fluids if you have a high temperature since a fever can dehydrate you.

For those with a fever or aches and pains, Roberts suggested taking ibuprofen and acetaminophen. Just make sure to check in with a doctor first to see if it’s safe for you to take the medication. If you do use them, make sure to swallow the pills after the shot. Some doctors recommend not taking them before vaccination since they may blunt the immune response, Roberts said.

Other than that, remember that time is on your side. These side effects are typically short-lived and you should bounce back within a couple days.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


National survey shows hesitancy about vaccines this fall, with 37% of respondents believing they don't need vaccination
by Ohio State University Medical Center
September 12, 2024

With flu season just around the corner and COVID-19 cases on the rise, a new nationwide survey from The Ohio State University Wexner Medical Center reveals hesitancy around vaccines this fall. The new data comes just as this year's flu shot rolls out and following the FDA's approval of an updated round of COVID-19 vaccines.

The national poll of 1,006 people found more than one-third (37%) have gotten vaccines in the past but do not plan to this year. The same percent of respondents said they don't need any of the vaccines surveyed in the poll, including flu, COVID-19, pneumococcal and respiratory syncytial virus (RSV).

Other survey results found:
  • A slight majority (56%) of adults have gotten or plan to get the flu shot this fall.
  • Less than half (43%) have gotten or plan to get the COVID-19 vaccine.
  • Adults age 65 and older are the most likely to get recommended vaccines.
"We're at the start of respiratory virus season when you have the triple threat of flu, COVID-19 and RSV. Unfortunately, there is a lot of misinformation about vaccinations, but the reality is that they are safe and highly effective in preventing serious illness and death. Older adults, people with certain chronic medical conditions and those who are pregnant are especially at risk during respiratory virus season," said Nora Colburn, MD, medical director of clinical epidemiology at Ohio State's Richard M. Ross Heart Hospital.


CDC's recommended vaccines
  • Flu: Annual vaccination is recommended for everyone aged 6 months and older.
  • COVID-19: Updated vaccination is recommended for everyone aged 6 months and older.
  • RSV: Everyone aged 75 and older, adults aged 60-74 who are at increased risk of severe disease, and pregnant people during weeks 32-36 from September to January.
  • Pneumococcal: Everyone younger than 5 years and aged 65 and older. Additionally, vaccination is recommended for children and adults at increased risk of severe disease.
"Vaccinations play a critical role in helping to keep individuals and communities healthy. Other things you can do are to stay home when sick, avoid those who are sick and wear a mask if you're not feeling well and going out of your home. All of these things can help prevent you from getting sick and spreading it to others," Colburn said.


Survey methodology

This survey was conducted on behalf of The Ohio State University Wexner Medical Center by SSRS on its Opinion Panel Omnibus platform. The SSRS Opinion Panel Omnibus is a national, twice-per-month, probability-based survey. Data collection was conducted from August 16–August 18, 2024, among a sample of 1,006 respondents.

The survey was conducted via web (n=975) and telephone (n=31) and administered in English. The margin of error for total respondents is +/-3.8 percentage points at the 95% confidence level. All SSRS Opinion Panel Omnibus data are weighted to represent the target population of U.S. adults ages 18 or older.
Provided by Ohio State University Medical Center
 

Heliobas Disciple

TB Fanatic
(fair use applies)


A new type of RNA could enhance vaccines and cancer treatments
by Jessica Colarossi, Boston University
September 11, 2024


a-new-type-of-rna-coul.jpg

Development and characterization of a fully modified saRNA vaccine against SARS-CoV-2. Credit: Nature Biotechnology (2024). DOI: 10.1038/s41587-024-02306-z

It all started in the lab. Two Boston University doctoral students, Joshua McGee and Jack Kirsch, were creating and testing different types of RNA—strands of ribonucleic acid, built from chains of chemical compounds called nucleotides that help carry out genetic instructions in cells. They were determined to see whether RNA sequences crafted with small changes to their nucleotides can still work. After running dozens of experiments, they hit a dead end.

"At first, it was a failure," McGee says.

Decades of research have uncovered the mysteries of RNA in living cells. Without it, our cells couldn't perform fundamental tasks, like constructing other cells, carrying amino acids from one part of the cell to the other, or mounting immune responses to viruses.

But, more recently, scientists have figured out how to harness RNA to make treatments aimed at fighting genetic diseases and cancer. They've also learned how to use messenger RNA (mRNA) to make COVID-19 vaccines. The experiments that McGee and Kirsch perform are aimed at using RNA to deliver lifesaving drugs and create more effective vaccines than we have today.

Working alongside Mark Grinstaff, BU's William Fairfield Warren Distinguished Professor of biomedical engineering and chemistry, and Wilson Wong, a College of Engineering associate professor of biomedical engineering, they started talking about what to do next—and what to do with the chemical components left over from the initial experiments.

They decided to focus on modifying the chemical structure of a lesser-known type of RNA, called self-amplifying RNA (saRNA), which is manufactured in the lab and replicates itself multiple times in a cell to produce a higher number of the proteins it's programmed to make.

The new method worked: Their modified saRNA was replicating itself in a petri dish.

"Our reaction to that was a lot of excitement, but also the normal scientist thinking, 'Did we do this right?'" McGee says. "We went back to do it again and again. And we got the same results."

The results kicked off a yearlong research project that moved from Grinstaff's chemistry lab to Wong's genetics engineering lab to BU's National Emerging Infectious Diseases Laboratories (NEIDL), where they tested their modified saRNA as a vaccine against the COVID-19 virus. They found that a lower dose of their new vaccine in mice protected them from the disease just as well as current mRNA vaccines. Their findings are published in Nature Biotechnology.

It'll be years of further testing before this vaccine can be approved for humans. Even though there is one type of saRNA vaccine—approved last year for use in Japan—the researchers hope their modified version will make the technology more appealing to drug manufacturers, as well as overcome the challenges of using saRNA as a vaccine.

"The challenge with regular self-amplifying RNA is that there are two competing processes—the RNA is trying to make more and more protein, and at the same time the immune system is degrading it," says Grinstaff.

Standard mRNA COVID vaccines tell cells to produce a spike protein that mimics the real virus. That, in turn, causes the immune system to kick in and fight the virus. But an saRNA vaccine goes one step further by repeating those instructions to the cell over and over, making more of the machinery to create the spike proteins. More proteins means you don't need as high a dose and the immune system remembers how to fight the virus over a longer period of time.

"So the idea is that this could give you a long duration of protein expression, even when using a lower dose," Grinstaff says.

Another challenge is that saRNA could create a much-too-strong reaction that can lead to uncomfortable side effects—worse than those of current COVID vaccines, which typically cause some people to develop a mild fever or aches.

Grinstaff, Wong, and the team collaborated closely with Florian Douam, a BU Chobanian & Avedisian School of Medicine assistant professor of virology, immunology, and microbiology and a core faculty member at NEIDL. He and his team performed a study—called a "viral challenge"—to evaluate whether a COVID-19 vaccine built with the modified saRNA technology could protect mice more effectively against severe COVID-19 disease than earlier saRNA and mRNA vaccines.

"The viral challenge aspect was particularly important," Douam says. "It exposed how a very low dose of this novel saRNA technology is able to protect mice against lethal disease much more effectively than traditional saRNA and mRNA COVID-19 vaccines at a similar dose." Douam says that the new vaccine, which incorporates modified nucleotides called m5C (5-methylcytidine), also triggered very low levels of inflammation upon vaccination comparable to mRNA vaccines.

"There is still plenty of work to be done to unveil all of the advantages of this technology over other existing RNA vaccine approaches," Douam says. But this was a promising start.

The next question is whether their modified saRNA can provide longer-lasting protection against virus infection compared to existing RNA-based vaccines at a similar dosage.


More promising treatments


Besides COVID vaccines, the team's well-tolerated saRNA could open the door for other types of treatments and gene therapy.

"At the end of the day, this is a protein-producing system," Wong says, "a gene-delivery system."

For a genetic disorder, saRNA could be programmed to produce a missing gene or replace a defective one, Wong says. For treating lung, breast, and other cancers, "we can have it produce an anticancer drug for disease that requires a high dose and a lot of protein being made."

"That's why we're really excited about our self-amplifying RNA technology—because we think we can lower the dose that's needed to enable some of these therapeutic applications," Wong says. "That's how we envision it."

"There's so much work that we're doing now to further understand what we have discovered," says McGee, who is co-advised by Wong and Grinstaff. "There are a lot of publications out there that suggested research on saRNA would also fail. This made me realize that it's okay to try things that other people think might fail, because, who knows, they could be wrong."

More information: Joshua E. McGee et al, Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency, Nature Biotechnology (2024). DOI: 10.1038/s41587-024-02306-z
Journal information: Nature Biotechnology
Provided by Boston University
 

Heliobas Disciple

TB Fanatic
(fair use applies)


COVID-19 cases surge in Russia, key regions hit hard as infections rise by 20 percent
James Josh Fact checked by:Thailand Medical News Team
Sep 11, 2024

COVID-19 infections are once again on the rise in various regions of Russia, creating a concerning uptick in cases as autumn approaches. From August 26 to September 1, the number of new cases surged by 20% compared to the previous week. A total of over 21,000 people across the country contracted the virus during this period, with specific regions facing more significant outbreaks. This COVID-19 News report will delve into the current situation, the regions most affected, and what health experts are saying about the future trajectory of the pandemic.


Rising Numbers in Russia: A Closer Look at Key Regions
In Russia as a whole, the number of weekly cases rose sharply, with 21,000 people diagnosed between August 26 and September 1. The hardest-hit areas were Moscow, with more than 5,000 cases, and St. Petersburg, which reported over 2,000. Other regions such as the Samara and Nizhny Novgorod areas also saw an alarming rise in infections, with 1,400 and 880 cases, respectively. The Krasnodar Krai reported 718 cases, adding to the growing list of regions under pressure from the virus.

However, the neighboring regions of Sverdlovsk and Chelyabinsk showed the highest regional increases. In the Sverdlovsk region, more than 400 new cases were recorded, including one fatality. Similarly, the Chelyabinsk region reported 277 cases and one death. Other regions such as Yugra (87 cases), Kurgan (74 cases), and Yamal (54 cases) reported smaller but notable spikes in infections.

Meanwhile, in Tyumen, a region that has often managed to maintain lower case counts compared to neighboring areas, the numbers are rising. Over the past week, 184 new cases of COVID-19 were confirmed in Tyumen, with 27 individuals requiring hospitalization. Fortunately, no deaths were recorded. Nevertheless, the growing number of infections has led local health authorities to remain on high alert.


Hospitalizations and Mortality Rates
As COVID-19 cases continue to rise, so do hospitalizations. Between August 26 and September 1, nearly 3,000 people were hospitalized across Russia due to the severity of their symptoms. This represents a staggering 52.3% increase from the previous week. A significant portion of these hospitalizations occurred in 45 constituent regions of Russia, with 14 of these regions experiencing rates higher than the national average.

Although the majority of cases have been mild, there have still been fatalities. During this period, 28 people lost their lives to the virus. This is a marked increase compared to the previous week when 17 people succumbed to the disease. For many, this increase in both deaths and hospitalizations is an alarming sign of what may come if the current trends continue.

Despite these rising numbers, many health officials and experts are cautious about declaring a new pandemic wave. According to Russian infectious disease specialist Dr. Evgeny Timakov, the peak of COVID-19 cases is expected to hit around late September. While this could strain healthcare facilities, R ospotrebnadzor, Russia’s consumer health watchdog, insists that there is no immediate cause for panic. This article highlights the importance of continuous monitoring and emphasizes that, as of now, there is no evidence pointing to a new pandemic wave.


Acute Respiratory Infections Compound the Crisis
While COVID-19 remains a pressing concern, it is not the only virus threatening public health. The Samara region, in particular, has reported a dramatic rise in acute respiratory viral infections (ARVI), which are overwhelming hospitals and clinics. As of last week, more than 9,200 people were diagnosed with ARVI in the Samara region, which is 27.8% higher than the epidemic threshold. Shockingly, the infection rate among residents over 15 years old has exceeded the threshold by 92%.

The rise in ARVI cases comes amid the circulation of other respiratory pathogens such as parainfluenza, adenoviruses, and rhinoviruses, making the situation even more complicated. Health authorities are closely monitoring the situation as ARVI, combined with COVID-19, could result in an overburdened healthcare system, especially as the cold season begins.


Public Response and Safety Measures
Despite the escalating numbers, Russian authorities have not yet implemented new lockdown measures or other strict public health interventions. However, health experts urge caution. Local governments in affected regions like Tyumen and Sverdlovsk have recommended reinforcing preventive measures, such as mask-wearing in crowded public places and practicing good hand hygiene. This is particularly crucial in schools, workplaces, and public transportation, where the virus spreads quickly.

In Tyumen, for example, officials took a preventative measure by closing down several kindergarten groups at the end of August. This decision was made after an outbreak of enterovirus infections in young children, highlighting the vulnerability of group settings during periods of heightened viral activity.


Future Outlook: Can Russia Curb the Spread?

As Russia braces for a potential peak in cases later in September, health officials and citizens alike are preparing for what could be a challenging few months. The rapid rise in both COVID-19 and ARVI cases is troubling, but it is hoped that the summer’s vaccinations and natural immunity from prior infections will provide some buffer against a major outbreak.

Experts continue to monitor the situation, and the public is encouraged to stay informed about any new developments. By practicing preventive measures and seeking medical attention when necessary, individuals can play a role in helping to reduce the spread of the virus.

Numerous local Russian news outlets have also reported about the COVID-19 surge as well.


Будет новая пандемия? В Тюменской области растет число заболевших COVID-19

Заболеваемость COVID-19 в РФ за неделю выросла на 20%
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Raccoon dogs, minks in focus as China animal study uncovers dozens of new viruses
Viruses found include 36 new ones and 39 at ‘potentially high risk of cross-species transmission’, including human spillover, study says

Josephine Ma
Published: 6:02pm, 6 Sep 2024|Updated: 6:09pm, 6 Sep 2024

A study of more than 450 dead fur animals in China has revealed dozens of new viruses and cross-species infections, including some with high risk of human spillover.

Raccoon dogs and minks carried the highest number of potentially high-risk viruses, according to findings published in the latest issue of Nature, including a mink virus closely related to those only found in bats so far.

“Fur farming represents an important transmission hub for viral zoonoses”, the study authors said, with some viruses having already spilled over to humans.

Scientists from several Chinese universities and some from overseas took part in the research, including Edward Holmes, a virologist at The University of Sydney.

In early 2020, Holmes helped Shanghai virologist Zhang Yongzhen become the first to publicise the genome sequence for Sars-CoV-2 – the coronavirus strain that causes Covid-19. The sharing of the data with the international community helped to speed up vaccine development as the pandemic raged.

For the farm animal study, which began in 2021, the scientists collected internal tissues from 461 animals that had died of disease across China.

A total of 28 species were involved, mostly farm animals reared for their fur, for use in Chinese medicine, or as food.

They found 125 virus species from the samples, including 36 that were new viruses and 39 at “potentially high risk of cross-species transmission, including zoonotic spillover”.

The intensive breeding environment in animal farms made them a possible bridge for virus spillover, the scientists said.

They said 11 of the viruses had already spilled over to humans while some others had a high risk of zoonosis – or crossing the species barrier to infect humans.

“These data also reveal potential virus transmission between farmed animals and wild animals, and from humans to farmed animals, indicating that fur farming represents an important transmission hub for viral zoonoses,” according to the paper.

“We identified a Mers-like coronavirus – Pipistrelles bat coronavirus HKU5 – in two mink from a single farm associated with an outbreak of pneumonia, as well as the first report, to our knowledge, of a coronavirus in nutria.”

Mers, or Middle East respiratory syndrome, is a coronavirus and therefore related to Sars, or severe acute respiratory syndrome.

The scientists said they were most concerned about the Pipistrellus bat coronavirus HKU5 in mink, as its lineage was closely related to viruses that had been only found in bats.

Bat viruses have a history of recombination, meaning they can mix and form new strains when they infect the same host.

Other causes of concern were a new coronavirus – tentatively named as “rabbit coronavirus” – and the divergent and high amount of coronaviruses found in the organs of the dead animals, according to the study.

Cross-species transmission from animals to humans caused pandemics in the past, the scientists warned.

“Many countries farm particular fur animals for national and international fur trade exchanges.

Importantly, fur animals such as foxes, civets and mink have been suggested to be the potential hosts for a variety of human viruses,” they said.

“As humans regularly come into contact with farmed animals, it is critical to improve our knowledge of the viruses that circulate among farmed fur animals and their potential for zoonotic transmission.”

The paper does not mention any finding of Sars-CoV-2, the Covid-19 virus, among the dead animals studied.

In an emailed response to the South China Morning Post, co-author Holmes said the study was not aimed at finding the origin of Covid-19 because it would be impossible to find the “intermediate” host that might have passed the virus to humans such a long time after the pandemic emerged.

In 2022, Holmes co-authored a paper for Science saying that the earliest Covid-19 events suggested the pandemic probably did begin in the Huanan Seafood Wholesale Market, where the first known case was detected in late 2019.

He also rejected the theory that the virus could have leaked from a laboratory in Wuhan.

The latest findings pointed to the need to monitor farmed animals to prevent future pandemics, Holmes told the Post.

“While our paper is not about Covid origins, it clearly shows that viruses can move from wildlife species like bats into farmed species like mink. This leads to human beings being exposed to animal viruses. To me, this is exactly the sort of process that ultimately leads to pandemic viruses like Sars-CoV-2.”

The authors clarified that small sample sizes in some cases and the focus on dead animals meant the study could not “provide information on the viruses that circulate in healthy farmed fur animals”, while “the concentration on respiratory and gastrointestinal symptoms” meant they could not “identify viruses that are present only in other tissues”.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Needle-free vaccines going to trial in astounding Australian-led innovation

An Australian invention that delivers vaccines without a jab is ready for clinical trials. This is how you can help.

Robyn Riley
September 12, 2024 - 12:01AM

A tiny skin patch half the size of a postage stamp is about to be tested in Melbourne to see if it can safely deliver a needle-free vaccine for bird flu.

The Australian invention has tiny prongs that give a vaccine dose directly to immune cells below the skin surface.

If clinical trials are successful it could be an alternative to the traditional method of an injection into a muscle and may even offer a way to give multiple vaccines at the same time.

Potentially it could even deliver multiple vaccines needle-free to babies, helping to reduce the number required to protect children under the age of five.

Called High-Density Microarray Patch (HD-MAP) technology, it is being developed by Australian biotech company Vaxxas with studies funded by the US Government.

The company’s CEO David Hoey said global pandemic threats required the world’s health organisations to have better and more accessible vaccine delivery options.

Doherty Clinical Trials’ chief medical officer James McCarthy is leading the bird flu vaccine trial in Victoria.

He described the device as having microscopic prongs just visible to the human eye, with the vaccine coated on the end of each prong.

“The prongs are pushed into the skin with a simple device and, over two minutes, they deliver the vaccine into the tissue just under the skin,” Professor McCarthy said. “It stings a little, but is not as painful as using a needle and syringe.”

He said it was exciting technology that offered a lot of advantages globally including against a future pandemic where the technology could enable a faster and broader vaccination response.

“It is also being investigated to see if it can avoid the need for expensive and complex cold-chain delivery,” Professor McCarthy said.

“That’s the long-term possibility, that it could even be mailed to people to use in the home so that’s a great advantage.

“Vaxxas is also looking at putting more than one vaccine on these patches.

“So although the bird flu vaccine we’re testing at the moment is exciting, there will also be the possibility of combining different vaccines together eventually.”

Clinical trials in Queensland are already testing the skin patch as a vaccine for seasonal flu, Covid-19 and measles and rubella with “promising” results.

To join this trial at Doherty Clinical Trials participants must be aged between 18 and 50 years, in good health and available to visit its East Melbourne facility for nine visits over 13 months.

Volunteers will have a medical examination by doctors, including a physical examination, measuring vital signs and conducting blood tests.

The University of Melbourne subsidiary, Doherty Clinical Trials was established by the Doherty Institute to accelerate the development of novel medicines and vaccines through bespoke early phase clinical trial solutions.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


China’s Wuhan virology institute creates nasal Covid-19 vaccine for ‘future pandemics’
‘Broad spectrum’ nanovaccine can target multiple coronaviruses, says team at institute once in spotlight over Covid lab leak theory

Victoria Bela
Published: 9:00pm, 11 Sep 2024

Researchers from the Wuhan Institute of Virology in China have developed a nanovaccine candidate that could offer universal protection against all major Covid-19 variants – as well as protect against future coronavirus mutants with pandemic potential.

The institute – which has engaged in bat coronavirus research for years – has in recent years been embroiled in controversy, and scrutiny from countries including the United States, over accusations that the Covid-19 pandemic originated from a lab leak at its facilities.

But with consistent support from the Chinese government, researchers at the institute have continued their studies into Sars-CoV-2, the coronavirus that causes Covid-19.

Although existing vaccines have been used to help prevent the spread of Sars-CoV-2 and reduce mortality, none offer broad or universal protection against all forms of the virus, according to the team behind the nanovaccine.

The team discovered that combining coronavirus epitopes – parts of antigens that trigger the immune system – with the blood protein ferritin could produce an intranasal nanoparticle vaccine that protected against multiple variants of Sars-CoV-2.

These included Delta, Omicron and the WIV04, an early strain isolated from a patient in Wuhan, where the pandemic was first reported.

The nanoparticle vaccine, which was tested on mice, also showed the potential to provide long-lasting and broad protection against other types of coronavirus. This could prove effective in preventing the infection and spread of future mutant variants.

“The ongoing and future pandemics caused by Sars-CoV-2 variants and mutations underscore the need for effective vaccines that provide broad-spectrum protection,” the researchers wrote in a paper published in peer-reviewed journal ACS Nano in June.

“Our constructed nanovaccine targeting the conserved epitopes of the pre-existing neutralising antibodies can serve as a promising candidate for a universal Sars-CoV-2 vaccine.”

There is still no universal scientific consensus on the origins of Sars-CoV-2. Scientists have published research over the last few years both in support of the lab-leak theory and others, including “zoonotic spillover” – or a direct cross-species spread from animal to human.

Since 2020, researchers from the Wuhan institute have been involved in over 230 research papers relating to Sars-CoV-2, including six published so far this year, according to a list updated by the institute.

Although the global risk levels from the Covid-19 virus are nowhere near those in the early days of the pandemic in 2020, the coronavirus threat is not behind us.

Two of the major outbreaks of this century have been caused by a similar type of coronavirus – the Covid-19 pandemic and the 2003 severe acute respiratory syndrome (Sars) outbreak.

Middle East respiratory syndrome (Mers), also caused by a coronavirus, has sickened several thousand people since it was first identified in 2012.

Researchers warn that the continuous mutation of the coronavirus will continue to give rise to new mutant strains, some of which could prove infectious enough to cause future outbreaks and even another global pandemic.

Scientists are also studying the long-term consequences of the Covid-19 pandemic, including the impact the virus may have on brain development.

With the threat of future diseases along with the ongoing impact of new Covid-19 variants, the development of broad-spectrum vaccines is increasingly necessary.

Nanovaccines are an “excellent vaccine platform” that are more easily produced than traditional vaccines like live attenuated or inactivated vaccines, but still elicit robust and long-lasting immune responses, the team wrote in their paper.

Covid-19 vaccines typically induce the release of neutralising antibodies against the spike glycoprotein (S) or the receptor binding domain, which allows the virus to “dock” with cells.

Existing nanovaccine candidates mainly target S1, a subunit of the spike glycoprotein, rather than the S2 subunit, as it is “less accessible for immune recognition,” the researchers said.

The S2 subunit is more homologous and conserved across coronaviruses, indicating that it could offer a better target for broad spectrum vaccines.

Previous research has found pre-existing antibodies in cells that recognise coronavirus antigens, which primarily target S2 and can impede the entry of Sars-CoV-2 into cells.

To produce their nanovaccine, the team combined their epitopes – short peptides with conserved sequences in S2 – with ferritin derived from the Helicobacter pylori bacteria, which was expressed in Escherichia coli cells where it self-assembles into nanoparticles.

The nanoparticles are then separated and concentrated from the bacterial cells to obtain the vaccine, which can be delivered intranasally instead of through injection.

Mice given the nanovaccine, followed by two boosters within 42 days, produced higher levels of the antibody Immunoglobulin G than the controls, which persisted even after six months.

When mice given the nanoparticles were infected with different variants, including Omicron and Delta, they showed improved resistance to virus-induced lung symptoms.

The antibodies induced by the vaccine can bind to epitopes from different coronavirus strains – including Mers, bird flu and swine flu coronaviruses – exhibiting broad neutralising activities, according to the researchers.

The nanoparticle vaccine “has the potential protective capability as a broad spectrum vaccine against various [coronaviruses]”, the team wrote.

The team previously showed that following a similar strategy to produce a nanovaccine could offer protection against the mosquito-borne Zika virus.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Doctors Predict What COVID Cases Will Be Like This Fall And Winter
Jillian Wilson
Thu, September 12, 2024 at 6:31 PM UTC

It feels impossible to go somewhere right now and not hear people coughing, sneezing and sniffling ? and that’s because COVID-19 is everywhere. If you haven’t been recently infected, you probably know someone who has.

According to wastewater data from the Centers for Disease Control, dozens and dozens of states have “very high” or “high” levels of the virus at the moment, which begs the question: What does this mean for the upcoming respiratory virus season when illnesses like COVID usually spike?

We asked experts what they think this summer COVID surge means for the next few months. All three experts said they’ve been surprised by surges and lulls time and time again, making it impossible to definitively say what will happen in the next few months ? but here are their best predictions:


Infections may start to slow down during the early fall.

Dr. Scott Roberts, a Yale Medicine infectious diseases specialist and the associate medical director in infection prevention at Yale New Haven Health in Connecticut said he expects COVID cases to decrease in the early fall for a period of time.

“With this atypical July through August surge, I would predict that we would undergo this pattern of falling cases that would extend through at least the next few months,” he said. “So, I would probably predict we’d have a relatively decent end of September, October period, just based on the natural pattern we’ve seen with these waves.”

“There’s still a ton of COVID going around right now. In some places, it might be just starting to kind of slow down, possibly maybe enter a period of decline, but really, there’s a lot of COVID happening right now,” said Dr. Jennifer Nuzzo, a professor of epidemiology and the director of the Pandemic Center at Brown University School of Public Health in Rhode Island.

According to the CDC, test positivity rate is slightly down from the end of August. Roberts does not expect these predicted lower case numbers to stick around long-term, though.


COVID cases will likely rise again as we get later into fall and winter.

“I anticipate that we will see higher numbers of COVID beginning with the fall and winter months,” said Dr. Matthew Binnicker, the director of clinical virology at Mayo Clinic in Rochester, Minnesota.

“The fall and winter months typically see a higher rate of respiratory viruses like [COVID-19] and influenza, as people are indoors and respiratory viruses like [COVID-19] seem to be able to survive or persist in the cooler temperatures, lower rates of humidity allow for the virus to be spread further,” he added.

Binnicker expects the rates to be even higher than what we saw during the summer surge, particularly during November, December and January.

Roberts said he also expects to see a winter wave, but thinks it’ll be lower than previous winters.

“Everybody who’s being infected right now, I think the odds of them getting infected over the winter are much less because they’re having an immunity boost to the current circulating variants,” Roberts said. “So unless there’s some sort of variant from left field that we’re not expecting, I would predict that this winter wave in December, January, February would be lower than that of the past few winters. But I still do expect an uptick.”


All that said, COVID is still an unpredictable virus.

As mentioned above, COVID-19 is unpredictable — we know this from the last four-plus years of the virus. While it’s helpful to anticipate what COVID-19 may do in the coming months, no one really knows.“I could imagine a scenario in which we have a little bit less COVID this fall and winter, because so many people got sick over the summer. But I also don’t know what’s going to happen with how the virus mutates and if a new variant or a subvariant emerges that could change things,” Nuzzo said.

The unpredictability of COVID means it’s best to do what you can to not get sick or lessen the illness if you do end up infected.“The best step is to get the updated COVID vaccine ... it’s been designed to elicit immune response against one of the more recent SARS-CoV-2 variants,” Binnicker said.You can get the new shot now as long as it’s been two months since your last COVID-19 vaccine. The CDC also states if you recently had COVID, you can wait three months to get the jab — but you don’t have to. If you don’t know when to get the new shot, talk to your doctor who can help you make the best choice for you.Additionally, if you have any signs of COVID-19, stay home, Binnicker said. This will help keep other folks from getting sick. If you do have to go out, wear a mask, he noted.


COVID-19 isn’t the only respiratory virus that’ll be going around this fall and winter.

COVID-19 is a hard thing to predict, it doesn’t fit the regular respiratory virus pattern, which is a rise and peak during the fall and winter.“I’ve been wrong in my [COVID-19] predictions before ... but I can tell you with almost absolute certainty, we’re going to see RSV and flu go up since those have been pretty nonexistent since last winter,” Roberts said. “Flu and RSV ... are much more tried and true with the patterns of a seasonal winter spike.”

To protect yourself from the flu, get your flu shot, which Roberts recommends getting in October. There’s also a RSV vaccine for older people and high-risk folks.With coughing, sneezing, fever, body aches and headache being overlapping symptoms for these respiratory viruses, it’s important to take a COVID test, Binnicker said. If your test comes back negative, call your doctor who can test you for flu and RSV. This way, you can get the necessary medical treatment to get better and keep those around you well, too.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Researchers warn that SARS-CoV-2 RBD mutations Q498H and R493K could enhance human-animal cross-transmission
Sebastian Lavoie Fact checked by:Thailand Medical News Team
Sep 12, 2024

In a recent study, researchers from Michigan State University-USA and the University of Arkansas-USA have raised concerns over specific mutations in the SARS-CoV-2 virus, particularly mutations Q498H and R493K, which have emerged in certain new Omicron variants and sub-lineages. These mutations, according to the study, may enhance the virus's ability to jump between humans and animals, heightening the risk of future zoonotic infections. This Medical News report will explore the findings in detail, shedding light on the potential implications of these mutations.


The Role of Mutations in Viral Transmission

SARS-CoV-2, like all viruses, undergoes mutations as it spreads and evolves. Some of these mutations can enhance the virus’s infectivity in humans, while others may alter its ability to infect animals. The researchers focused on mutations in the virus’s receptor-binding domain (RBD), the region of the spike protein that allows the virus to bind to the ACE2 receptor in host cells. The stronger the bond between the RBD and the ACE2 receptor, the more infectious the virus becomes.

Using advanced modeling techniques, including a multitask deep learning model called MT-TopLap, the researchers examined how these RBD mutations might impact the virus’s ability to cross between species. By analyzing binding free energy (BFE) changes, they identified key mutations that could make SARS-CoV-2 more efficient at infecting animals and potentially jumping back to humans.

This article emphasizes that cross-species transmission has been a concern since the early days of the COVID-19 pandemic. The virus is believed to have originated in animals before making the leap to humans. As it continues to evolve, the risk of it jumping to other animal species, such as cats, bats, or deer, and then back to humans remains a possibility. The mutations Q498H and R493K are of particular concern because they may make this process easier.


Analyzing the Risk: How RBD Mutations Affect Transmission

The key focus of the study was to understand how these specific RBD mutations might influence SARS-CoV-2’s ability to infect both humans and animals. The MT-TopLap model was trained using deep mutational scanning (DMS) data, allowing it to predict changes in BFE due to mutations across multiple species. The model was able to provide insights into how the virus’s RBD interacts with the ACE2 receptors of not only humans but also animals like cats, bats, deer, and hamsters.

The study’s findings indicated that the mutations Q498H in the SARS-CoV-2 virus and R493K in its BA.2 variant could significantly enhance the virus’s ability to bind to the ACE2 receptors of animals. This enhanced binding suggests that these mutations could increase the virus’s potential for cross-species transmission, making it more likely to jump from humans to animals and vice versa.

Moreover, the researchers highlighted that while the virus may adapt to infect animals, this does not necessarily mean it will lose its ability to infect humans. On the contrary, mutations that enhance cross-species transmission may also result in a virus that is better equipped to infect humans after adapting to animal hosts. This is particularly concerning as it could lead to the emergence of new, more infectious variants that are capable of causing outbreaks in both human and animal populations.


The Implications of Human-Animal Cross-Transmission
The potential for SARS-CoV-2 to spread between humans and animals presents significant public health challenges. If the virus can establish itself in animal populations, it could create reservoirs from which it might re-emerge, even after human infections have been controlled. This could make it more difficult to fully eradicate the virus and could lead to new outbreaks driven by animal-to-human transmission.

In the United States, for example, a significant percentage of white-tailed deer have been found to be infected with SARS-CoV-2, raising concerns that the virus could become endemic in wildlife. Similarly, there have been documented cases of household pets, including cats and dogs, contracting the virus from their owners. These animals developed antibodies, suggesting that they had mounted an immune response to the infection. This further underscores the importance of understanding the dynamics of cross-species transmission.

By identifying the RBD mutations that enhance the virus’s ability to infect animals, researchers hope to better anticipate potential zoonotic outbreaks and develop strategies to mitigate the risks. The study suggests that these mutations could lead to the emergence of new variants that are not only more infectious but also more capable of evading the immune responses of both humans and animals.


Deep Mutational Scanning and Viral Evolution

One of the key tools used in this study was deep mutational scanning (DMS), a technique that allows scientists to analyze the effects of thousands of mutations on viral proteins. DMS has proven invaluable in studying SARS-CoV-2 because it provides a detailed understanding of how mutations affect the virus’s ability to bind to ACE2 receptors and evade immune responses.

The researchers combined DMS data with topological deep learning (TDL), a cutting-edge approach that uses topological fingerprints to predict how mutations will affect protein function. By integrating these techniques, the team was able to create a model that accurately predicts how SARS-CoV-2 mutations will impact viral transmission across species. This could provide a valuable tool for forecasting the evolution of the virus and for designing vaccines and treatments that target future variants.

The MT-TopLap model, which was pre-trained on multiple DMS datasets, was able to predict the BFE changes caused by RBD mutations in various species. This allowed the researchers to pinpoint mutations that could enhance human-animal transmission and potentially lead to the emergence of new, more dangerous variants.


Conclusion: A Call for Vigilance and Further Research

The findings of this study highlight the ongoing need for vigilance in monitoring SARS-CoV-2 mutations and their potential to facilitate cross-species transmission. The mutations Q498H and R493K, in particular, pose a risk of enhancing the virus’s ability to jump between humans and animals, potentially leading to new outbreaks and complicating efforts to control the pandemic.

As the virus continues to evolve, it is crucial that scientists and public health officials remain alert to the possibility of new variants emerging from animal populations. By studying how these mutations affect viral transmission, researchers can develop more effective strategies for preventing and mitigating future zoonotic outbreaks.

The study findings were published in the peer-reviewed journal: Computers in Biology and Medicine.

 

Heliobas Disciple

TB Fanatic
(fair use applies)


Discovery of SARS-CoV-2 in ground water sources for consumption and baths in Iran sparks alarms among researchers
Charles Tee Fact checked by:Thailand Medical News Team
Sep 12, 2024

In a groundbreaking discovery, researchers in Iran have identified traces of the SARS-CoV-2 genome in groundwater sources used for consumption and bathing. This alarming finding, which was conducted over a two-year period, has raised serious concerns about the potential risks to public health. The study involved scientists from the Research Institute for Gastroenterology and Liver Diseases at Shahid Beheshti University of Medical Sciences in Tehran. The team collected groundwater samples seasonally from multiple sites around Tehran to assess the presence of the virus.

This Medical News report examines the findings, implications, and the urgent call for action from the global research community to address the contamination of groundwater, a vital resource in many parts of the world.


A Novel Discovery in Waterborne Transmission

The presence of SARS-CoV-2 in wastewater has been well documented worldwide, but its detection in groundwater has been a relatively new development. The Iranian study is one of the first to report traces of the SARS-CoV-2 RNA in groundwater, raising concerns about the possibility of waterborne transmission in certain environments.

The study, which took place from 2021 to 2023, focused on 12 groundwater sites, and researchers tested 96 samples. The findings were significant because, although the virus was only detected in one sample, it demonstrated that even in low prevalence, groundwater could be a potential source of exposure to SARS-CoV-2. The virus was detected using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to identify the E and S genes of the virus. The study findings underscore the importance of further research into groundwater contamination and the role it could play in public health.


How the Study Was Conducted
The research team used a well-established method known as virus adsorption-elution (VIRADEL) to concentrate the virus in the water samples. They added avian coronavirus as a control and proceeded with RNA extraction from the groundwater. The use of RT-qPCR allowed the team to detect the virus at concentrations of 2/53 × 10³ and 3/16 × 10³ genome copies per liter for the E and S genes, respectively. The positive sample was collected in February 2022, during a significant wave of COVID-19 cases in the region.

The detected variant was identified as BA.1 Omicron, one of the variants that spread globally during the pandemic. The sequencing of the SARS-CoV-2 genome from the groundwater sample was followed by a phylogenetic analysis to determine the mutation patterns of the virus. The researchers observed 10 mutations in the spike gene, including several located in the receptor-binding domain (RBD), which is responsible for the virus's ability to bind to human cells.


Implications for Public Health
The discovery of SARS-CoV-2 in groundwater is particularly concerning because groundwater is often used as a source of drinking water and for agricultural irrigation in many regions, including parts of Iran. The contamination of such a vital resource could pose a significant risk to public health, especially in areas where sanitation systems are less developed or where wastewater is improperly treated.

The study’s findings also raise questions about the possibility of fecal-oral transmission of SARS-CoV-2 through contaminated water. The presence of E. coli and other fecal coliforms in the samples further supported the hypothesis that the virus might enter the groundwater system through inadequately treated wastewater or other contamination routes. This points to the need for improved wastewater treatment and water safety measures, particularly in urban and densely populated areas.


Potential Environmental and Health Risks
The environmental risks posed by groundwater contamination are not limited to human health. The use of contaminated water for irrigation could affect the safety of food crops and potentially introduce the virus into the food chain. Vegetables irrigated with contaminated groundwater might carry traces of the virus, and although SARS-CoV-2 has a relatively low survival rate in aquatic environments compared to other viruses, the risk should not be ignored.

Another major concern is the leachate from COVID-19 victims’ graves, which could seep into groundwater systems. In Iran and other countries with high infection rates and high mortality from COVID-19, this raises additional environmental concerns about the long-term impacts of mass burials and their potential to contaminate water supplies.


A Call to Action: Strengthening Water Safety Measures

The study’s findings are a stark reminder of the critical need for water-based epidemiology to monitor and mitigate the risks of viral contamination in water sources. Improved water safety measures, including proper sanitation, treatment of wastewater, and monitoring of groundwater systems, are essential to preventing the spread of SARS-CoV-2 and other viruses through water systems.

While the Iranian study is one of the first to document SARS-CoV-2 in groundwater, similar research conducted in other parts of the world has also highlighted the importance of monitoring water sources for viral contamination. For example, earlier studies in Mexico detected traces of the virus in groundwater, although findings were inconsistent across different regions.

The Iranian researchers emphasized the importance of developing standardized procedures for detecting viruses in groundwater and other water matrices. The current lack of standardized methods makes it difficult to compare findings across different regions and could lead to underreporting of the presence of SARS-CoV-2 in water systems. Further research is needed to better understand the conditions under which the virus can survive and the factors that contribute to its degradation in water.


Conclusion: Groundwater Monitoring as a Tool for Early Detection
The Iranian study highlights the critical need for continuous monitoring of groundwater and other water sources for SARS-CoV-2 and other viral pathogens.

This approach can serve as an early warning system for detecting spikes in infection rates and the emergence of new viral variants, particularly in areas with limited access to clinical testing. By detecting viral RNA in water, public health authorities can take proactive measures to mitigate the risks of outbreaks and protect communities from potential waterborne transmission.

As the world continues to grapple with the ongoing impact of the COVID-19 pandemic, the findings from this study serve as a reminder of the importance of environmental surveillance in controlling the spread of the virus. Efforts to improve water safety and sanitation systems, particularly in regions with high population densities, must be prioritized to reduce the risk of viral transmission through contaminated water.

The study findings were published on a preprint server and is currently being peer reviewed.

 

Heliobas Disciple

TB Fanatic
(fair use applies)


New COVID-19 spike across 23 American states revealed through wastewater analysis
James Josh Fact checked by:Thailand Medical News Team
Sep 12, 2024

As the COVID-19 pandemic evolves, new challenges continue to emerge, with one of the most recent being the rise of coronavirus activity detected through wastewater in the United States. A study led by the U.S. Centers for Disease Control and Prevention (CDC) has found that 23 states are currently experiencing “very high” levels of COVID-19 in wastewater, despite a general decline in reported cases across the country. This Medical News report will explore these key findings and delve into the specifics of the current COVID-19 situation in the U.S., as uncovered by wastewater analysis.

As concerns about COVID-19 have lessened across much of the U.S., the U.S. CDC has shifted its focus to wastewater surveillance to track the virus. This method has become an essential tool because it can detect the presence of the virus in a community even before symptoms arise, providing a more comprehensive view of the current situation.

From August 25 to August 31, 2024, data from the CDC revealed that 23 states reported “very high” levels of coronavirus in wastewater. Meanwhile, 22 other states experienced “high” levels. These findings underscore the fact that the virus continues to spread, especially in states across the southern and central U.S., despite the overall reduction in positive COVID-19 tests.


Wastewater COVID-19 State and Territory Trends

Of the 23 states, the following 16 states are showing extremely high levels of COVID-19 wastewater viral activity: Idaho, Nevada, California, South Dakota, Nebraska, Texas, Wisconsin, Illinois, Missouri, Alabama, Georgia, Virginia, Pennsylvania, New York, Connecticut and Massachusetts.


Key Findings: Variant Trends and Regional COVID-19 Activity
One of the significant factors behind the recent surge in COVID-19 cases is the emergence of new variants, primarily the KP.3.1.1 subvariant. This variant has been driving much of the recent increase in infections, with its unique mutations making it more transmissible. These mutations occur in the spike protein, which plays a critical role in how the virus infects human cells and how our immune system or vaccinations target the virus. Changes in the structure of this protein allow the KP.3.1.1 variant to spread more easily and potentially evade immunity, leading to more infections.

According to the U.S. CDC, as of August 31, the KP.3.1.1 variant accounted for over 40% of all COVID-19 cases in the U.S. in the previous two weeks. In addition, a group of variants known as the FLiRT variants accounted for more than 80% of cases during the same period. These variants, while more infectious, do not appear to cause severe symptoms in most individuals, leading to relatively low hospi talization and death rates.


However, the symptoms of COVID-19 remain varied, and individuals should stay vigilant. Common symptoms include fever, cough, shortness of breath, fatigue, muscle aches, loss of taste or smell, and gastrointestinal issues. More vulnerable individuals, such as the elderly or those with pre-existing conditions, are still at risk of severe illness and should take extra precautions.


Regional Discrepancies in COVID-19 Positivity Rates
The CDC also tracks COVID-19 positivity rates across the U.S., revealing significant regional differences. For instance, data collected from August 25 to August 31 showed that states in Region 6 (Arkansas, Louisiana, New Mexico, Oklahoma, and Texas) experienced the most significant decrease in COVID-19 positivity rates, with a drop of 4.4%. In contrast, Region 3 (Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, and West Virginia) saw a 3.6% increase in positivity rates during the same period. These regional variations highlight the uneven spread of COVID-19, with some areas seeing improvements while others face rising infections.

Across the U.S., the overall COVID-19 positivity rate was recorded at 16.3% for the last week of August, down slightly from the previous week’s 17%. Despite this decline, the ongoing presence of high viral activity in wastewater suggests that the virus continues to circulate widely in communities.


The Role of Wastewater in Future COVID-19 Tracking

Wastewater analysis is becoming a vital tool in the fight against COVID-19 because it provides a more reliable method of tracking viral activity. Unlike traditional testing, which can be influenced by factors such as access to testing kits or people choosing not to test, wastewater surveillance captures a broader picture of the virus’s spread in a community.

This method has proven particularly valuable during periods when official case numbers may be underreported, either due to testing shortages or because many individuals opt for at-home tests that go unreported. By analyzing wastewater, public health officials can gain early warning signs of rising COVID-19 cases and respond accordingly, whether by issuing public health advisories or ramping up healthcare resources.


Looking Forward: What to Expect Next

As COVID-19 continues to mutate and new variants emerge, the U.S. may experience more waves of infections. The KP.3.1.1 variant, which is currently the dominant strain, could potentially evolve further, posing additional challenges for public health officials.

However, vulnerable populations, including the elderly and those with underlying health conditions, remain at risk. It is essential to continue monitoring the spread of the virus and to take preventative measures, especially as the virus continues to evolve.

In conclusion, the recent rise in COVID-19 activity across 23 states, as detected through wastewater, highlights the ongoing challenges of controlling the virus. While case numbers may be declining, the presence of new variants and continued transmission in many parts of the country should serve as a reminder that COVID-19 is far from over. The use of wastewater analysis offers a promising tool for early detection, providing valuable insights into the virus’s spread and helping to guide public health responses.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Germany reports rise in COVID-19 infections with 6,215 new cases for epidemiological week 36
Nikhil Prasad Fact checked by:Thailand Medical News Team
Sep 13, 2024

Germany has seen a notable rise in COVID-19 cases for the 36th epidemiological week of 2024 (1st September to 7th September 2024), with 6,215 new cases reported by the Robert Koch Institute (RKI). This increase is part of an ongoing trend observed since early August, contributing to the overall stabilization of acute respiratory infections (ARE) in the population. Despite this uptick, the situation remains under control, with hospitalization rates staying relatively low. However, a large majority of the population appears to be sickly with many GPs reporting a variety of symptoms plaguing many including chronic fatigue, mobility issues, body pains, cognitive issues, sleep and eating disorders and breathing issues.

This Coronavirus News report delves into the key findings from the latest RKI report and provides an overview of the current respiratory disease landscape in Germany.

COVID-19 on the Rise: A Closer Look at the Numbers
According to the RKI’s latest weekly report, the number of new COVID-19 cases has risen from the previous week’s total of 5,706 to 6,215 in epidemiological Week 36. This increase is consistent with a gradual upward trend that began in Week 32 of 2024. While COVID-19 cases are rising, it is important to note that severe cases, particularly those requiring hospitalization, remain manageable. Of the newly reported cases, only 26% were hospitalized.


https://influenza.rki.de/Wochenberichte/2023_2024/2024-36.pdf

The increase in COVID-19 cases has also been reflected in the country's wastewater monitoring system. Since early August, the aggregated SARS-CoV-2 virus load in wastewater has shown a modest increase, signaling that more individuals are likely becoming infected with the virus.

It should be noted that that actual COVID-19 infection rates could be much higher than that reported as there is very little COVID-19 testing being conducted and test conducted in homes using rapid test kits are not included in any data and most hospitals or clinics do not run any COVID-19 test for very mild symptoms.


General Respiratory Illness Trends in Germany
In addition to the rise in COVID-19 cases, the RKI report indicates that the overall activity of acute respiratory infections (ARE) in Germany has remained stable compared to the previous week. Across both outpatient and inpatient settings, there has been no significant change in the number of doctor visits related to respiratory infections. The number of severe acute respiratory infections (SARI) has also remained steady, and the percentage of SARI cases diagnosed with COVID-19 has been stable at 9%.

The report estimates that around 4.4 million individuals in Germany experienced acute respiratory infections during this period, with rhinoviruses and SARS-CoV-2 being the predominant pathogens. Interestingly, the ARE rate among children has decreased, while rates among adults have risen slightly. Despite these changes, the overall ARE activity remains higher than usual for this time of year.


The Role of Sentinel Surveillance: Key Pathogens Detected
Germany’s National Reference Center for Influenza Viruses (NRZ) continues to play a vital role in tracking respiratory pathogens. In Week 36, a total of 62 sentinel samples were collected from 30 medical practices across the country. Of these, 32 samples tested positive for respiratory viruses, with rhinoviruses accounting for 24% of cases and SARS-CoV-2 for 21%. Parainfluenza viruses (PIV) made up 8% of positive cases, while human coronaviruses (hCoV) and adenoviruses each represented 2%.

Notably, no influenza viruses, respiratory syncytial viruses (RSV), or human metapneumoviruses (hMPV) were detected during this period. The lack of influenza and RSV detections suggests that these viruses may not be significant contributors to respiratory illness during the late summer months. However, rhinoviruses and SARS-CoV-2 remain active and continue to cause respiratory infections across the country.

This report highlights the importance of ongoing sentinel surveillance, which provides valuable data on the circulating respiratory viruses and helps inform public health responses.


Hospitalization Rates: A Stable Situation

The number of hospitalizations due to severe respiratory infections (SARI) has remained stable during epidemiological Week 36. About 9% of SARI cases were diagnosed with COVID-19, and fewer than 1% of cases were linked to influenza or RSV. The stability in hospitalization rates is encouraging, suggesting that the healthcare system is not currently under significant strain due to respiratory infections.

However, the report notes that the majority of COVID-19 hospitalizations occurred in older populations, particularly those aged 60 and above. This trend underscores the continued vulnerability of older adults to severe outcomes from COVID-19, even as the overall case numbers rise.


Wastewater Monitoring: Tracking the Virus’s Spread
The RKI’s wastewater monitoring system provides an additional layer of surveillance for tracking the spread of SARS-CoV-2. Since early August 2024, the aggregated SARS-CoV-2 virus load in wastewater has shown a slight but steady increase. This increase aligns with the rise in reported COVID-19 cases, suggesting that the virus is spreading more widely in the community.

The viral load in wastewater in North Rhine-Westphalia has been steadily increasing, with wastewater testing in Düsseldorf revealing a consistent rise in detected corona pathogens for the third consecutive time. In Bonn, this upward trend has persisted for nine weeks, while other measuring stations in Bielefeld, Dortmund-Scharnhorst, and Wuppertal also report growing numbers, according to the RKI.


Wastewater surveillance is a valuable tool for detecting trends in virus transmission, as it can provide early warning signs of increasing infection rates before they are fully reflected in clinical case data. In Week 36, data from 125 wastewater treatment plants were analyzed, and the findings suggest that the virus is becoming more prevalent in certain regions of the country.


Impact on Different Age Groups
The ARE and COVID-19 trends observed in Week 36 differ across age groups. While the incidence of acute respiratory infections has decreased among children, it has risen slightly among adults. In particular, younger adults (aged 15-34 years) have experienced a higher incidence of SARI, a trend that has been observed throughout the summer months.

At the same time, school-aged children (5-14 years) have also seen a resurgence in SARI cases after a brief decline in earlier weeks. The rise in SARI cases among these younger populations may be linked to increased social interactions following the summer holidays, as fewer restrictions and more indoor gatherings facilitate the spread of respiratory viruses.


Conclusion: The Current State of COVID-19 and ARE in Germany
Germany's COVID-19 situation continues to evolve, with 6,215 new cases reported in Week 36. While case numbers are rising, the healthcare system is managing the situation well, with stable hospitalization rates and a relatively low incidence of severe cases. The dominance of rhinoviruses and SARS-CoV-2 as the main respiratory pathogens underscores the importance of ongoing public health measures to reduce transmission, particularly among vulnerable populations such as older adults.

The increase in wastewater SARS-CoV-2 levels is an early indicator that COVID-19 may continue to spread in the coming weeks, although the overall impact on the healthcare system remains moderate. The RKI’s comprehensive surveillance systems, including sentinel monitoring and wastewater analysis, are critical in providing up-to-date information on respiratory disease trends and helping guide public health responses.
 

Zoner

Veteran Member
View: https://twitter.com/sensereceptor/status/1834622103590461599?s=12


"Why do I feel like 40% of the population is dead already?...It feels like our loved ones, many of them are gonna die or be disabled or never regain their former personalities...Humanity was stricken with a plague through this injection. It's the tenth plague."

DailyClout CEO, author, and professor Dr. Naomi Wolf (@naomirwolf) describes for Laura-Lynn Tyler Thompson (@LauraLynnTT) how she feels like 40% of the human population is "dead already." Wolf notes that with the COVID injections "humanity was stricken with a plague."

"I feel like 30%, 40% of the population just isn't there anymore," Wolf says. "They're walking around, but I feel like they're already dead...It feels like our loved ones, many of them are gonna die or be disabled or never regain their former personalities."

Furthermore, Wolf says that she's interviewed gynecologists and obstetricians who say that "women are in trouble." The physicians, Wolf says, say that women "have clots all over their bodies" and "don't know if they're going to survive." The physicians say "the women are hemorrhaging [and that] babies are in trouble [including from] chromosomal abnormalities."

Partial transcription of clip:

"I think we're midway or maybe a third of the way through the destruction of the world as we knew it.
And the destruction of of I mean, literally, I posted a couple of days ago, why do I feel like 40% of the population is dead already? You know, they're walking around, but I feel like they're already dead. And God forbid. You know? But but I feel like spiritually and something, you know, may have to do with this injection. I've written about that, how it kind of, damages the brain and damages the nervous system and may damage how we literally sense each other, the energy field that causes us to love each other and bond with each other, love God. But I do feel like 30%, 40% of the population just isn't there anymore. So even if we and and they're changed.

"Like, I keep thinking of that phrase, in the twinkling of of an eye, everything has changed. And if we're gonna be honest, and I'm getting chills even seeing this, the world we're in now is already on the other side of a great, devastation. And and there's no like, oh, that was bad. Let's just, you know, fix everything and go back to where we were in 2020. It doesn't feel like that. It feels like our loved ones, many of them are gonna die or be disabled or never regain their former personalities.

Our institutions are being revealed as totally corrupt and unsustainable. Our currency is, you know, revealed as hollowed out journalism. You said, why isn't this spontaneous journalism is a mockery of itself? You know, our republics, our representational government, are mockeries of themselves. You could call this a political problem, but it it's really also a a spiritual consequence. I mean, it's not just a spiritual problem. I think we're I think we're reaping what we sowed right now. You know? And and what we sowed was so bad, you know, so bad that it's it's not over. You know?

"I interview gynecologists and obstetricians, and they're like, women are in trouble. They have clots all over their bodies. I don't know if they're gonna survive. They're hemorrhaging. Babies are in trouble. There are chromosomal abnormalities. Humanity was stricken with a plague, you know, through this injection. It's like it's like the tenth plague. It's like the Egyptians and and the babies that, you know, just like okay. This is a plague. You're not gonna survive it, for a huge percentage of humanity."
 
Last edited:

Heliobas Disciple

TB Fanatic
(fair use applies)


Moderna scales back vaccine ambitions as COVID shot revenue plunges
Nathan Bomey
Sep 12, 2024

Moderna is dialing back its plans for new vaccines, shelving several key projects as it grapples with a sharp slowdown in COVID shot sales.

Why it matters: The company came to the world's rescue during the pandemic, but the pharmaceutical industry is still a what-have-you-done-for-me-lately business.

Between the lines: Moderna plans to "slow down the pace of new R&D investment, and build our commercial business," CEO Stéphane Bancel said in a statement.
  • It'll reduce annual R&D expenses from $4.8 billion in 2024 to $3.6B-$3.8B in 2027, including by ditching several programs.
The big picture: The company had been using the initial windfall of revenue it reaped from COVID shots to invest in new vaccines, hoping to develop a sustainable pipeline of future products.
  • It expects 10 to win approval in the next three years, including a combination flu-COVID vaccine.
Yes, but: Many of its future vaccines aren't moving quickly enough to bolster the top or bottom line.
  • The company's second-quarter revenue totaled $241 million, a 43% drop from a year earlier, which it said was "primarily attributable to decreased sales of the Company's COVID-19 vaccine."
  • The upshot is that Moderna isn't expected to turn a profit until 2028, according to a research note by Jefferies analyst Michael Yee cited by CNBC.
The impact: Moderna's stock fell over 12% Thursday, having tumbled from its all-time high above $449 in September 2021 — a wipeout of nearly $170 billion of market value over the three years.

The intrigue: In 2020, tackling COVID was a one-way ticket to a financial windfall.
  • But now the industry's obsession has moved on — most notably to lucrative weight-loss medications, which have triggered a sales and stock boom for the likes of Eli Lilly and Novo Nordisk.
  • Lilly today announced its latest move to capitalize on demand for its GLP-1 anti-diabetes and anti-obesity drugs: an $800 million investment in an Ireland factory to boost production of the treatments.
The bottom line: Moderna's technology is promising, but COVID vaccines are no longer enough to sustain the full scale of its R&D ambitions.
 
Last edited:

Zoner

Veteran Member
View: https://twitter.com/sensereceptor/status/1834622103590461599?s=12


"Why do I feel like 40% of the population is dead already?...It feels like our loved ones, many of them are gonna die or be disabled or never regain their former personalities...Humanity was stricken with a plague through this injection. It's the tenth plague."

DailyClout CEO, author, and professor Dr. Naomi Wolf (@naomirwolf) describes for Laura-Lynn Tyler Thompson (@LauraLynnTT) how she feels like 40% of the human population is "dead already." Wolf notes that with the COVID injections "humanity was stricken with a plague."

"I feel like 30%, 40% of the population just isn't there anymore," Wolf says. "They're walking around, but I feel like they're already dead...It feels like our loved ones, many of them are gonna die or be disabled or never regain their former personalities."

Furthermore, Wolf says that she's interviewed gynecologists and obstetricians who say that "women are in trouble." The physicians, Wolf says, say that women "have clots all over their bodies" and "don't know if they're going to survive." The physicians say "the women are hemorrhaging [and that] babies are in trouble [including from] chromosomal abnormalities."

Partial transcription of clip:

"I think we're midway or maybe a third of the way through the destruction of the world as we knew it.
And the destruction of of I mean, literally, I posted a couple of days ago, why do I feel like 40% of the population is dead already? You know, they're walking around, but I feel like they're already dead. And God forbid. You know? But but I feel like spiritually and something, you know, may have to do with this injection. I've written about that, how it kind of, damages the brain and damages the nervous system and may damage how we literally sense each other, the energy field that causes us to love each other and bond with each other, love God. But I do feel like 30%, 40% of the population just isn't there anymore. So even if we and and they're changed.

"Like, I keep thinking of that phrase, in the twinkling of of an eye, everything has changed. And if we're gonna be honest, and I'm getting chills even seeing this, the world we're in now is already on the other side of a great, devastation. And and there's no like, oh, that was bad. Let's just, you know, fix everything and go back to where we were in 2020. It doesn't feel like that. It feels like our loved ones, many of them are gonna die or be disabled or never regain their former personalities.

Our institutions are being revealed as totally corrupt and unsustainable. Our currency is, you know, revealed as hollowed out journalism. You said, why isn't this spontaneous journalism is a mockery of itself? You know, our republics, our representational government, are mockeries of themselves. You could call this a political problem, but it it's really also a a spiritual consequence. I mean, it's not just a spiritual problem. I think we're I think we're reaping what we sowed right now. You know? And and what we sowed was so bad, you know, so bad that it's it's not over. You know?

"I interview gynecologists and obstetricians, and they're like, women are in trouble. They have clots all over their bodies. I don't know if they're gonna survive. They're hemorrhaging. Babies are in trouble. There are chromosomal abnormalities. Humanity was stricken with a plague, you know, through this injection. It's like it's like the tenth plague. It's like the Egyptians and and the babies that, you know, just like okay. This is a plague. You're not gonna survive it, for a huge percentage of humanity."
This makes me think of the prophecy in the Bible that one third dies in the 6th Trumpet (Revelation 9) which is the last thing that happens before Jesus returns which is at the sounding of the 7th Trumpet (Revelation 11:15ff).
 

Heliobas Disciple

TB Fanatic



(fair use applies)

Florida discourages use of mRNA Covid vaccines in older adults
Berkeley Lovelace Jr. - NBC News
Fri, September 13, 2024 at 7:13 PM UTC

Even as the Covid wave in Florida continues, Gov. Ron DeSantis’ administration is once again advising against the mRNA vaccines: this time in the most vulnerable residents.

In updated guidance for health care providers released Thursday, the Florida Health Department and state Surgeon General Joseph Ladapo questioned the safety and effectiveness of the mRNA Covid vaccines from Pfizer and Moderna, including for older adults and people with underlying health problems. “Any provider concerned about the health risks associated with Covid-19 for patients over the age of 65 or with underlying health conditions should prioritize patient access to non-mRNA Covid-19 vaccines and treatment,” according to the state guidance.

Standing in opposition to advice from federal health agencies and other medical experts about the safety of the Covid vaccines, the Florida Health Department said the recommendation was based on high rates of immunity from prior infections and “currently available data.”

Without noting the high risk of serious Covid infection or hospitalization for older adults, the guidance listed safety concerns for the mRNA vaccines, including the risk of a rare heart condition called myocarditis, as well as the risk of POTS, or postural orthostatic tachycardia syndrome, a debilitating heart condition.

Numerous studies have shown that both Pfizer and Moderna’s vaccines are indeed associated with a small but increased risk of myocarditis. However, most cases occur in young men and most people make a full recovery. Studies have also shown that the risk of myocarditis is much higher with a Covid infection and is often more severe than the vaccine-associated condition.

A study published in Nature Cardiovascular Research? also found that people diagnosed with Covid are five times more likely to develop POTS after infection than after Covid vaccination, emphasizing the importance of the vaccine.

Dr. Paul Offit, a vaccine expert at Children’s Hospital of Philadelphia, said the Florida surgeon general's guidance is unnecessarily alarming people about the Covid vaccines.

"It's just such a dangerous game he plays," said Offit, who has served on the FDA's independent vaccine advisory committee. "You only have a roughly 1,000 times greater likelihood of dying [from Covid] if you're over 65 than if you're under 18."

"The mRNA vaccines are remarkably safe," he added.

New doses of the Pfizer and Moderna vaccines were approved by the Food and Drug Administration in August. They’re targeted to the KP.2 version of the steadily mutating virus and should provide good protection against severe illness, hospitalization and death, experts say.

The United States offers only one Covid vaccine that isn’t mRNA-based: Novavax. Novavax’s traditional protein-based shot offers an alternative vaccine technology to mRNA.

In a statement, a Novavax spokesperson said its updated vaccine is now available at thousands of retail and pharmacy locations nationwide.

The Florida Health Department did not immediately respond to a request for additional comment.

Dr. Isaac Bogoch, an infectious disease specialist at the University of Toronto, called Florida’s recommendation “unfortunate,” saying it could put older adults and people with underlying health conditions at risk.

“While the vaccine does not protect against infection nearly as well as it once did, there is very good data demonstrating how Covid vaccines can reduce the risk of severe manifestations of the virus in those who are at greatest risk,” said Boguch, who has no ties to the vaccine makers.

Covid cases remain high in the U.S. following a summer wave. Wastewater data collected between Aug. 25 and Aug. 31 shows that 23 states -- including Florida -- are reporting “very high” levels of the virus, according to the CDC. Emergency department visits and hospitalizations remain elevated as well, although they’re showing signs of declining. In Florida nursing homes, after declining from summer highs, Covid infections are ticking up again, according to CDC data.

The CDC currently recommends everyone ages 6 months and older get an updated Covid vaccine this fall from any of the three options.

This isn’t the first time Ladapo has ignored CDC guidance. Last year, Ladapo also recommended that Florida residents under the age of 65 not get the mRNA Covid vaccines, citing widespread immunity and “questions we have about safety and about effectiveness.”

“My judgment is that it’s not a good decision for young people and for people who are not at high risk at this point in the pandemic,” he said.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Surgery post-COVID: No need to wait more than two weeks, new study says
by Isabella Backman, Yale University
September 13, 2024

Postponing operations following a positive COVID-19 test may be creating unnecessary delays in elective surgeries, new findings suggest.

In the early days of the pandemic, the American Society of Anesthesiologists recommended delaying nonurgent surgeries by up to seven weeks following SARS-CoV-2 infection. These guidelines were based on research at the time that showed that COVID-19 was associated with an increased risk of post-operative difficulties including pulmonary complications.

Now, in the midst of the latest wave—predominantly driven by subvariants of omicron known as FLiRT and LB.1—many medical institutions continue to take conservative measures even though the newest infections have tended to be milder.

A new study shows that there is no significant benefit in delaying surgeries longer than two weeks after SARS-CoV-2 infection. The researchers published their findings in Annals of Surgery on August 1.

"The same mandate for postponing surgery that was necessary before isn't supported by the most recent evidence," says Ira Leeds, MD, assistant professor of surgery at Yale School of Medicine, who was the study's first author.

Following the onset of the pandemic, elective surgeries came to a screeching halt. "For the first six months to a year of the COVID-19 pandemic, unless there was a true urgency, cases were being routinely delayed based on local policies supported by society guidelines at the time," says Leeds.

Later on, as these procedures went back on schedule, surgeons grappled with how to provide patients with the beneficial outcomes of surgery while minimizing the risk of COVID-related post-operative complications. Given that both surgery and COVID-19 can place stress on organs such as the heart and lungs, surgeons took great precautions.

"The data at the time suggested that among those who were seriously ill from COVID-19, there were long-term sequelae [condition following prior disease/injury]," says Leeds. For example, these patients faced greater risks associated with mechanical ventilation and blood clots.

However, when later waves of COVID-19 eased in severity, surgeons had little guidance on whether weeks-long delays were still protecting patients, especially those who had mild or asymptomatic infections.


Surgery within two weeks of infection associated with adverse outcomes

In its latest study, Leeds' team used Veterans Affairs administrative data from April 2020 to September 2022 to identify more than 80,000 patients who had undergone an inpatient surgical procedure. The most common surgeries patients underwent were hernia repairs and knee replacements. Of this cohort, 16,000 had a positive COVID-19 test before surgery.

The researchers divided these patients into groups based on the number of days between the most recent positive test and the date of surgery. Then, they matched patients in the COVID-positive and control groups based on factors including which disease they were being treated for, which procedure they underwent, and which medical center they visited.

The researchers compared mortality within 90 days and post-operative complications within 30 days. Their analysis revealed that there were no significant differences between the groups—with the exception of those who had tested positive within two weeks before their surgery.

These patients were the only ones who had a higher risk of mortality and post-operative complications[BI1] —including cardiopulmonary complications, blood clots, and post-operative infections—compared to the controls.


The study offers evidence that previous guidelines for delaying surgery are no longer beneficial to patients—preventing them from receiving timely care while offering no further protection from COVID-related complications.

"If someone is being hospitalized for COVID a week before their surgery, and they can wait a couple of weeks, then, yes, they should," says Leeds. "But anything more than two weeks was not associated with better surgical outcomes."

More information: Ira L. Leeds et al, Postoperative Outcomes Associated with the Timing of Surgery After SARS-CoV-2 Infection, Annals of Surgery (2024). DOI: 10.1097/SLA.0000000000006227
Journal information: Annals of Surgery
Provided by Yale University
 

summerthyme

Administrator
_______________
(fair use applies)


Combined anti-seizure drug and omega-3 may lower COVID-19 risks
by Claire Kowalick, University of Texas Health Science Center at San Antonio
September 9, 2024


urologist-discovers-th.jpg

Valproic acid use is associated with diminished risk of contracting COVID-19, and diminished disease severity: Epidemiologic and in vitro analysis reveal mechanistic insights. Credit: PLOS ONE (2024). DOI: 10.1371/journal.pone.0307154

Ronald Rodriguez, MD, Ph.D., professor of medical education and urology at Joe R. and Teresa Lozano Long School of Medicine at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), has discovered that the combination of valproic acid and docosahexaenoic acid (DHA) may reduce the risk of contracting COVID-19 and lessen its severity, according to a study published in August.

The research appears in the journal PLOS ONE.

Valproic acid is a common anti-seizure medication, and DHA is a type of omega-3 fatty acid known to improve brain and heart health.

When the COVID-19 pandemic began in 2020, Rodriguez received a kidney transplant, raising his own concerns about being at high risk for infection and its complications. Rather than sitting back at home, the urologist shifted his focus and investigated potential treatments for COVID-19. Rodriguez drew from his background in virology and gene therapy and explored an effective and accessible solution to fighting the virus.

Rodriguez's previous adenoviral gene therapy research in prostate cancer had led him to explore the antiviral potential of valproic acid. Approved by the U.S. Food and Drug Administration, valproic acid showed promise in preventing the COVID virus from replicating, but initial doses proved potentially toxic.

"A combination of a nutritional supplement and an anti-seizure drug in the right ratios with the right timing could be very profound in inhibiting the development of and replication of COVID and more importantly, because of the way it works, there are a couple of thousand genes that are affected," Rodriguez said.

A review of electronic medical records data from more than 3 million patients showed those taking valproic acid were less likely to develop COVID-19, and those patients who tested positive for COVID-19 were less likely to be admitted to the emergency room, inpatient hospital and intensive care unit (ICU).

"Valproic acid in combination with DHA strongly activates ancient antiviral pathways against large classes of viruses in the cells that are usually repressed by viruses, like coronaviruses. When they get in, the first thing they do is repress many of these antiviral pathways. This combination drug overcomes that and then turns it on to a strong extent and those ancient pathways are able to rid themselves of the virus," Rodriguez said.

Rodriguez and his research team envision usage of the valproic acid combo as a short-term, preventive treatment to avoid getting COVID-19 or to lessen its severity, like how a Z-Pak, a short course of azithromycin, diminishes a bacterial infection.

For older adults, people who have health issues or those who are immunocompromised, this discovery could allow them to return to their normal routine and experience things they have not been able to since COVID began.

Rodriguez sees the study's results as an opportunity for the development of low-cost alternatives for treatment around the world where other medications are not available.

More information: Amanda Watson et al, Valproic acid use is associated with diminished risk of contracting COVID-19, and diminished disease severity: Epidemiologic and in vitro analysis reveal mechanistic insights, PLOS ONE (2024). DOI: 10.1371/journal.pone.0307154
Journal information: PLoS ONE
Provided by University of Texas Health Science Center at San Antonio
Oh, dear Lord! Depakote (valproic acid). Black box warning for causing severe blood urea nitrogen buildup... several people ended up in dementia wards who just had screwed up blood chemistry from the Depakote.

It's worth the risk for someone with a seizure disorder. It saved our son's life when he was 16, after a bad concussion. And almost killed him at 21 when he suffered a seizure after a bad car wreck, and they prescribed it again, because it had been "well tolerated "!!

Taking it to "reduce COVID risk" is insane!

Summerthyme
 

Heliobas Disciple

TB Fanatic
Oh, dear Lord! Depakote (valproic acid). Black box warning for causing severe blood urea nitrogen buildup... several people ended up in dementia wards who just had screwed up blood chemistry from the Depakote.

It's worth the risk for someone with a seizure disorder. It saved our son's life when he was 16, after a bad concussion. And almost killed him at 21 when he suffered a seizure after a bad car wreck, and they prescribed it again, because it had been "well tolerated "!!

Taking it to "reduce COVID risk" is insane!

Summerthyme

I certainly hope no one here tries any of these newfangled remedies. But I post them because if they do work, and if things get very very dire, as in the 'Geert variant" showing up and killing everyone, and if very short term use can literally save your or a loved one of your's life, then having the info to show your doctor may be something to have tucked away on a back burner. But NO ONE should try this, or order these drugs from India or anything, by themselves. Like you said, this is a very powerful drug, it's not relatively harmless like ivermectin and should not be taken without medical surveillance. And ONLY if you are literally going to die and all other options have been expended and only if your doctor agrees. The doctor who did the study himself said it could be toxic. So let's wait for further studies and safe ways to do this if indeed it helps... btw, he's in Texas, so he's in the USA and may be easy to contact should the need arise. hopefully it never does for anyone reading this.

HD
 

Heliobas Disciple

TB Fanatic
(fair use applies)


The Origin of COVID–Beyond Natural or Lab Theories, There Is a Third Possibility
The hot debate over the origin of the COVID-19 virus has persisted for four years. How can we reconcile countervailing views?

By Yuhong Dong M.D., Ph.D.
September 14, 2024 Updated: September 15, 2024

The COVID-19 pandemic has come to an end. The number of acute cases has substantially decreased, people are returning to the office, and its prevalence in social media has all but dried up, with a potential new pandemic waiting on the horizon. However, before we move on, it’s important to reflect and ask: What caused the biggest pandemic of the 21st century?

After four years the question of how the virus found its way to humans has yet to reach a definitive conclusion.

There are currently two prevalent theories: One involves natural origins and the other involves lab derivation. Many, however, have overlooked a third possibility—one that we have yet to uncover.


Unicorn Virus

Much like the mythical unicorn, which represents something rare and extraordinary, the COVID-19 virus poses a unique set of challenges and dangers unlike those presented by any other virus we have encountered, making it a formidable and unprecedented threat to global health.

The COVID-19 virus’s unprecedented features—pathogenicity and transmissibility—are beyond what any virologist or doctor has previously encountered.

The original Wuhan COVID-19 virus could spread widely throughout the body, starting in the lungs and affecting various vital organs, including the brain, heart, blood vessels, liver, kidneys, and intestines.

Other viruses, such as the SARS virus, can also affect multiple organs, though not as broadly or severely as COVID-19. Most SARS complications have been self-limiting or reversible, although serious illness can sometimes result. In contrast, lethal complications such as heart failure, acute cardiac injury, and pulmonary embolism have been more commonly reported in COVID-19 patients. The flu virus infects far fewer organs and is much less severe than the original Wuhan COVID-19 virus.


COVID-19 can attack almost every part of the body due to several key factors:
  • ACE2 receptor binding: The virus has used its key—or spike protein—to bind to the angiotensin-converting enzyme 2 (ACE2) receptor, which is the gatekeeper of our cells, allowing the virus entrance.
  • Inflammation and cytokine storm: Once inside, the spike protein triggers inflammation, which can cause an extreme immune response (cytokine storm) that can lead to multiple organ failure.
  • Blood vessel damage: The spike protein can damage blood vessels, causing blood clots in vital organs that can lead to severe complications such as heart attack, stroke, and sudden death.

1. Natural Origin Theory

One of the major proposed causes of COVID-19 is rooted in a natural origin.

The virus can’t survive outside of a living organism—coronaviruses that cause severe diseases in humans usually have a natural reservoir, which is often bats. These reservoirs allow the virus to persist in nature and occasionally jump to humans or other animals, leading to outbreaks.

However, before they can cause disease in humans, an intermediate host is also needed. For example, the intermediate hosts of SARS and MERS are civets and camels, respectively.

For COVID-19, however, there are two key reasons why many challenge the natural origin possibility.


No Confirmed Natural Host

Despite extensive investigative efforts, no animals have been confirmed as the natural host of COVID-19.

The COVID-19 virus cannot infect bat cells directly, suggesting that bats are unlikely to be its natural host.

Peter Daszak’s publication has indicated that the COVID-19 virus was not found in pangolins (scale-covered mammals) in the wild or trade markets, so they are unlikely to be the intermediate host of the COVID-19 virus. Furthermore, pangolins live remotely from humans and are, therefore, unlikely to serve as intermediate hosts.

Uncommon animals traded at the Huanan Seafood Market, where most of the initial human cases were centered around, were initially assumed to be potential hosts of the virus. Some environmental swab samples from the market tested positive. However, no samples collected from those animals were found to carry the virus.

Furthermore, the so-called “patient zero” and one-third to half of the first batch of reported patients had no exposure to the Huanan Seafood Market. This fact suggests that the virus may have circulated in the community before being detected at the market.

Looking back, Jesse D. Bloom from Fred Hutchinson Cancer Research Center, identified a deleted dataset containing COVID-19 virus sequences from even earlier Wuhan epidemic patients, which he recovered from the National Institutes of Health’s archived database. Bloom conducted a genomic analysis, reaffirming that the Huanan Seafood Market was not the initial source of the virus outbreak.

Even though the virus’s spike protein can infect ferrets and cats, there is no convincing epidemiological or genomic evidence that these animals contributed to the early stages of the COVID-19 outbreak.


Unique Features Defy Odds

All coronaviruses have a spiky crown composed of spike proteins. The spike protein is divided into two parts: S1 and S2.
  • S1 is the binding component analogous to the biting of a door key, which inserts into the lock. It allows for the virus to attach to host cells.
  • S2 acts as the key’s base, or bow, supporting S1 and facilitating the unlocking process.
The “keys” of the COVID-19 virus—specifically, its spike protein—can be inserted into the lock via ACE2 receptors in our bodies more easily and quickly than those of other close relatives. This contributes to its high transmissibility and widespread impact.

After the COVID-19 virus initially attaches to the ACE2 receptor, a “scissor” enzyme called FURIN in the human body cuts between the S1 and S2 of the spike protein. This cleavage allows the virus to bind to ACE2 more seamlessly. The S2 subunit then fuses with the human cell membrane, stabilizing the binding of the S1 subunit with ACE2.

Scissors function like keys with sawtooth patterns that fit perfectly into locks. Strikingly, the COVID-19 virus has precisely the required human scissor-cut point—12 additional nucleotides—in the location between the S1 and S2 subunits of its spike protein. This insertion is perfectly positioned for human enzymes to cleave the spike protein efficiently, which helps the virus enter human cells.

“SARS-CoV-2 is the only one of more than 800 known SARS-related coronaviruses that possesses an FCS [FURIN cleavage site],” stated Richard H. Ebright, Board of Governors professor of chemistry and chemical biology at Rutgers University, during a June 18 congressional hearing.

“Mathematically, this finding—by itself—implies that the probability of encountering a natural SARS-related coronavirus possessing an FCS is less than one in 800,” he added.

Other unique genetic codes of the COVID-19 virus have further reduced the odds of natural evolution.
“Based on these features,” the probability of it having naturally evolved from its natural ancestor virus is “less than one in 1.2 billion,” according to Dr. Steven Quay, a former faculty member at Stanford University School of Medicine, who testified at the hearing, supported by his analytical report.

This number is roughly calculated based on the phylogenetic tree theory. Even the genes of its closest relative virus, RaTG13—claimed to be the ancestor of COVID-19 by virologists from Wuhan—are only 96 percent identical to the COVID-19 virus, with more than 1,000 nucleotide differences.

According to molecular clock theory, it would take a long time—potentially several hundred thousand years—for the virus RaTG13 to naturally evolve into COVID-19, and there is no evidence to support such a lengthy evolutionary period. Consequently, scientists do not convincingly regard RaTG13 as the ancestor virus of COVID-19.

To put it simply, virologists cannot identify a reasonable ancestor virus for the COVID-19 virus based on current scientific theories. Nevertheless, there is some debate over these calculations, and not all experts rule out natural evolution.

Meanwhile, the Wuhan Institute of Virology (WIV) was located in the same city where the COVID-19 pandemic originated. WIV has a long history of researching bat-related coronaviruses and SARS-like viruses. The institute has also done a significant amount of gain-of-function (GOF) research, which involves enhancing a virus’s functions.

The WIV naturally drew the world’s attention and became the focal point of the origin debate for the COVID-19 pandemic.


2. Lab Origin Theory

Before we delve into lab origin, we should make one thing clear: Whether the COVID-19 virus came from the Wuhan lab or not, the lab’s history of risky and unethical research—which operates under the Chinese Communist Party (CCP)—is a root problem that needs to be dealt with.

The COVID-19 outbreak originated in a city where the world’s most advanced laboratory research on SARS-like viruses has been conducted. This is the main reason the lab-origin scenario was considered.


Risky Research

In the Wuhan lab, virologists have used bat coronaviruses to manipulate SARS-like viruses for at least a decade.

In 2010, for the first time, Wuhan virologists discovered that coronaviruses use the spike protein as a key to bind to ACE2 receptors, which are widely distributed on the surface of the cells of the body’s vital organs.

In 2013, they isolated a specific bat coronavirus (WIV1) that bore a type of spike protein that can bind to human ACE2.

In 2015, they edited the genes of natural viruses and engineered a new SARS-like virus that can infect human cells and jump from animals to humans.

A leaked NIH report reported that WIV created novel SARS-like viruses that can reproduce up to 10,000 times more copies of the original virus in genetically engineered mice expressing human ACE2 receptors, mimicking the human infection.

Apart from the naturally occurring bat virus (WIV1), the other coronaviruses found to bind to human ACE2 receptors are the SARS virus, COVID-19 virus, and the purported four created by the WIV through GOF studies—the three viruses mentioned in the above leaked NIH report and the SHC014-MA15 virus reported in the 2015 Nature Medicine study.

In 2021, The Intercept released a leaked research proposal called DEFUSE, submitted in 2018. This proposal contained a gain-of-function research plan to insert the specific cleavage site—FURIN—into the virus genes.

Though the viruses engineered by WIV have not been proven to be the same as those of COVID-19 viruses, WIV intends to alter and enhance the functions of bat coronaviruses.

Some argue that research conducted by WIV was done to better understand natural coronaviruses and their transmission with no surreptitious motives.


Eventful Period: October Through November 2019

CCP reported that the first case of COVID-19 occurred on Dec. 1, 2019, with the Wuhan Huanan Seafood Market as ground zero.

Multiple investigative reports have revealed that a severe, mysterious infection had already silently emerged in Wuhan at least two months before.

1. A group of U.S. scientific researchers, mainly from the University of California San Diego, examined the genomic data from the first cases of COVID-19 and used a scientific model to determine when the virus started infecting people. Their study suggests infection began between mid-October and mid-November 2019 in Hubei Province, China.

It should be noted that this and other genomic studies were retrospective and can’t definitively confirm transmission, although these findings point to the possibility.

2. According to the China surveillance data of Wuhan influenza-like-illness (ILI) presented to the World Health Organization (WHO), a steep increase (Fig. 1) appeared in the last week of November 2019 (Nov. 24–30), rapidly exceeding the trend across 2016–2018.

If that week’s ILI cases were caused by COVID-19 infection, considering an incubation period of two to 14 days, the infection-occurring period would fall into the week of Nov. 16 or earlier—the same time frame as reported by the above-mentioned U.S. genomic study report.

Moreover, the WHO report also highlighted an unexplained increase (Fig. 2C) in lab test-negative ILI cases in Wuhan in mid-November 2019. Meanwhile, a 2022 published study indicates that those influenza-negative ILI cases may have served as potential COVID-19 transmission.

3. Diplomats stationed at the U.S. Consulate General in Wuhan attested valuable first-hand experience of an unusual, mysterious outbreak in Wuhan in October 2019. Subsequently, U.S. personnel decamped from China.

The deputy consular chief at the U.S. Consulate in China, Russell J. Westergard, later wrote in State Magazine:

“By mid-October 2019, the dedicated team at the U.S. Consulate General in Wuhan knew that the city had been struck by what was thought to be an unusually vicious flu season. The disease worsened in November. When city officials began to close public schools in mid-December to control the spread of the disease, the team passed the word to Embassy Beijing and continued monitoring.”

4. A surveillance report on sewage by the Italian Department of Environment, Health, and Nutrition, and Veterinary Public Health indicates that traces of the COVID-19 virus had been found in wastewater samples from Italy as early as Dec. 18, 2019.

There is a potential answer for how COVID-19 cases could have come to Europe so early:

The 2019 Military World Games—a kind of Olympics for soldiers—was held in Wuhan starting Oct. 18 and lasted nine days. Nearly 10,000 military athletes from more than 100 countries, including those from major European countries, participated.

It is reported that athletes from Germany, Italy, France, and Sweden became ill after their trip to Wuhan. Notably, these countries were the hardest hit early in the pandemic.

[continued next post]
 

Heliobas Disciple

TB Fanatic
[continued from post above]

The Missing Pieces in Lab Origin

Put simply, the Chinese lab has been conducting risky studies. Additionally, the CCP appears to have been hiding the facts about when COVID-19 first started—as they have a record of doing with other outbreaks, such as the 2003 SARS outbreak.

Therefore, many scientists have leaned toward the Wuhan lab leak hypothesis.

However, one question is overlooked: Were the WIV virologists even capable of creating the COVID-19 virus, the virus that infected hundreds of millions of people worldwide, paralyzing the world’s economy and causing the biggest pandemic since the Spanish Flu in 1918?

There is no smoking gun-level evidence that WIV created the same virus as COVID-19. The viruses produced from the GOF research found in WIV are still very different from the COVID-19 virus, though they have similar features.

The odds of fabricating the unique composition of the COVID-19 virus gene is around 1 in 1 billion.

Could WIV virologists have beaten the odds? Do virologists have such skill to control their GOF research outcome completely?

Having a goal and experimenting in the lab doesn’t necessarily result in the desired outcome. WIV may wish to increase the function of the bat-derived coronavirus, but they might neither have been able to design the virus that caused a global pandemic nor control the outcome of their GOF research process.

Gigi Kwik Gronvall, a professor in environmental health and engineering, and a senior scholar at the Johns Hopkins Center for Health Security, commented in a Hopkins Bloomberg Public Health article, “If I was able to ‘reasonably anticipate’ what happened in the lab, I would have gotten my PhD in six months instead of four years.”

On the one hand, manipulating viruses could result in the creation of something extremely harmful; on the other hand, it may also lead to a virus that is less potent than COVID-19.

We have no idea without further investigation that WIV deliberately created COVID-19. Current speculation is based on circumstantial observations.


3. The Third Option Theory

Science can’t explain everything.

If neither the natural nor the lab origin definitively explain the emergence of the COVID-19 virus, this raises the possibility that our current scientific theories may be too limited to fully account for its origin. In other words, a third option—of which we are still unaware—could be possible.

Science has greatly advanced our understanding of the world, providing explanations for countless phenomena through observation, experimentation, and empirical evidence.

Nevertheless, it has its limitations—numerous fundamental scientific questions remain unanswered.

In 2021, the journal Science published 125 questions that cannot be explained by contemporary scientific theories. These questions spanned a breadth of research, including the fields of astronomy, physics, mathematics, chemistry, medicine, life sciences, neuroscience, ecology, energy science, and artificial intelligence.

For instance, the origins of humans and human consciousness are still largely not elucidated and researchers continue to puzzle over such topics, although progress has been made in their understanding.

While Charles Darwin proposed the theory of evolution 165 years ago, he could not explain the origin of many biological species. There are numerous mysteries about species evolution that Darwin could not explain, which often frustrated him.

One notable example lies in the sudden appearance of flowering plants in the Cretaceous strata about 110 million years ago. In an 1879 letter to his close friend, botanist Dr. Joseph Hooker, Darwin referred to the rapid diversification of higher plants as an “abominable mystery.”

Such mysteries abound and underscore the limitations of contemporary science. As we continue to explore, it’s vital to acknowledge that certain higher concepts may lie beyond the reach of scientific inquiry, encouraging us to adopt a broader perspective.

When science hits a ceiling, we can better understand life’s origins only by breaking through. We need to discard outdated notions to simplify our understanding of life’s origins, including the emergence of the COVID-19 virus.


CCP Should Be Held Accountable


While the virus’s origins remain a mystery, we cannot overlook the WIV risky gain-of-function research. When humans manipulate nature without adhering to ethical guidelines, the potential for unforeseen disasters increases dramatically.

The WIV has crossed established boundaries of safety and ethics. Whether the engineered viruses are released from their labs or not, their reckless experiments have placed the global population at substantial risk.

We must conduct a thorough investigation into the lab’s documentation of the virulent viruses and animals they have been studying, as they have consistently obstructed access to experts and investigations.

Moreover, since the COVID-19 outbreak, the CCP has repeatedly delayed reporting and attempted to cover up the situation, hindering a coordinated global response.

China was once famous for its authenticity and morality. After the CCP took over in 1949, under the totalitarian regime, ethics became loose and fear rose. People with power dared to do risky things, and when disastrous events occurred, various parties involved wanted to be clear of suspicion.

Regardless of the ultimate origin of the virus, the CCP’s totalitarian regime, lack of accountability, and opaque policies have led to the harm of millions of lives. They must be held accountable for their actions.

While the CCP must be held accountable for the disastrous global impact of the COVID-19 pandemic, the ultimate origin of the virus may lie beyond the laboratory and current scientific understanding, as many unknowns still exist. It is essential for us to remain open-minded, appreciate what we have, and uphold tradition and human values to better protect ourselves from future pandemics.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Dutch study warns that repeated COVID-19 mRNA vaccinations affect immune response in older adults
Sebastian Lavoie Fact checked by:Thailand Medical News Team
Sep 16, 2024

A recent study conducted by researchers at the National Institute for Public Health and the Environment (RIVM) in the Netherlands has shed new light on how repeated COVID-19 mRNA vaccinations affect the immune system of older adults. The study focused on the changes in antibody responses among individuals aged 65 to 83 who received multiple doses of the vaccine. This COVID-19 News report delves into the key findings and explores how the repeated vaccinations may influence immune functions, particularly in older populations.

The study examines the way repeated mRNA vaccines lead to a class switch in antibodies and the subsequent effects on immune functionality. The study team were particularly interested in the shift in antibody types in older adults and how this could impact vaccine efficacy.


Understanding the Immune Response to COVID-19 mRNA Vaccines
Previous research claimed that the COVID-19 mRNA vaccines are highly effective at boosting immunity by stimulating the production of antibodies that target the SARS-CoV-2 spike protein. These antibodies are critical for neutralizing the virus and preventing severe illness. However, as the global vaccine rollout continued, researchers observed that the nature of the antibody response changed with each additional booster dose, particularly in older adults.

In the initial doses, the vaccine primarily induces antibodies belonging to the IgG1 and IgG3 subclasses, which are proficient at neutralizing the virus and activating immune cells such as natural killer (NK) cells. These antibodies are vital for eliminating infected cells and preventing the spread of the virus within the body.


The IgG4 Class Switch and Its Implications
One of the most intriguing findings from the study is the discovery of a class switch from IgG1 and IgG3 to IgG4 after repeated mRNA vaccinations. This class switching refers to the process by which the immune system produces different types of antibodies, each with unique functions. Researchers observed that after the third vaccination, there was a significant increase in IgG4 antibodies, which are less effective at neutralizing viruses and activating immune cells compared to IgG1 and IgG3. The switch to IgG4 is thought to occur because of prolonged exposure to the spike protein, either through infection or repeated vaccinations.

Unlike IgG1 and IgG3, IgG4 has a unique structural property called Fab-arm exchange, which allows it to bind to two different antigens at once, reducing its ability to form strong complexes and trigger immune responses. This change could have profound implications for how well the immune system responds to future exposures to SARS-CoV-2.


Reduced NK Cell Activation and Immune Efficiency
A crucial part of the study focused on the ability of antibodies to activate NK cells, which play a key role in clearing infected cells. The researchers measured

NK cell activation in response to the spike protein in blood samples from older adults after their second, third, and fifth vaccine doses. The results showed a clear decrease in NK cell activation as the proportion of IgG4 antibodies increased. This means that as the immune system produces more IgG4 antibodies, its ability to mount a robust response against the virus may be compromised.

Additionally, researchers found that the efficiency of the complement system - a crucial part of the immune system responsible for marking pathogens for destruction - also decreased with the rise in IgG4 levels. The complement system relies heavily on IgG1 and IgG3 to function effectively, and the shift to IgG4 could impair its ability to fight infections.


Comparing Younger and Older Adults

The study also compared antibody responses between older and younger adults. While both age groups experienced an increase in IgG4 after repeated vaccinations, older adults exhibited a more pronounced shift. This could be due to age-related changes in the immune system, which tend to make older individuals less responsive to vaccines and more susceptible to infections.

Researchers noted that younger adults maintained higher levels of IgG1 and IgG3 even after receiving their third dose of the vaccine. This suggests that their immune systems were better able to preserve the types of antibodies that are most effective at neutralizing the virus and activating immune cells.


Impact on Vaccine Effectiveness

One of the most important questions arising from this study is whether the increase in IgG4 antibodies will affect the overall effectiveness of the COVID-19 mRNA vaccines. The researchers emphasized that IgG4 antibodies are not inherently harmful; in fact, they play a critical role in regulating the immune system and preventing excessive inflammation. However, the reduced capacity of IgG4 to activate NK cells and the complement system raises concerns about whether repeated vaccinations might diminish the body’s ability to clear the virus efficiently.

It’s important to note that the vaccines remain highly effective at preventing severe disease and death, even in older adults who experience this class switch. However, the study's authors suggest that further research is needed to fully understand how the long-term use of mRNA vaccines will influence the immune system, especially in vulnerable populations like the elderly.


Conclusions and Future Research

The findings from this study offer valuable insights into the complex dynamics of the immune response to COVID-19 mRNA vaccines. The class switch from IgG1 and IgG3 to IgG4 highlights the adaptability of the immune system, but it also raises important questions about how this shift affects the body's ability to fight off infections. Additional research is needed to explore the mechanisms behind this class switching and to determine whether alternative vaccination strategies might be more effective for older adults.

In conclusion, repeated COVID-19 mRNA vaccinations in older adults lead to a significant increase in IgG4 antibodies, which are less effective at activating key immune functions. While the vaccines continue to provide strong protection against severe illness, understanding these shifts in immune response is crucial for optimizing future vaccination strategies, especially for vulnerable populations. This study underscores the need for ongoing research to ensure that booster campaigns remain effective as the pandemic evolves.

The study findings were published in the peer-reviewed journal: Immunity & Ageing.

 

Heliobas Disciple

TB Fanatic
View: https://www.youtube.com/watch?v=M4yslK5zgTw
New COVID Variant: What You Need to Do Now
Vejon Health
Streamed live September 16, 2024
17 min 08 sec

In this informative video, we break down the latest COVID variant that is making headlines. Understanding how this new strain works and what it means for our safety is crucial. We’ll explain the symptoms to watch for, how it spreads, and the latest recommendations from health experts.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Study reveals how COVID-19 infection can cause or worsen diabetes
by Julie Grisham, Cornell University
September 16, 2024

Researchers from Weill Cornell Medicine have used a cutting-edge model system to uncover the mechanism by which SARS-CoV-2, the virus that causes COVID-19, induces new cases of diabetes, and worsens complications in people who already have it. The team found that viral exposure activates immune cells that in turn destroy beta cells, the pancreatic cells that produce insulin.

The study is published in Cell Stem Cell.

"There has long been a hypothesis in the field that certain viral infections may trigger type 1 diabetes," said co-corresponding author Shuibing Chen, director of the Center for Genomic Health, the Kilts Family Professor of Surgery and a member of the Hartman Institute for Therapeutic Organ Regeneration at Weill Cornell Medicine. "But we were able to show how this happens in the context of COVID-19 infection."

"When someone has severe COVID-19, of course the first priority is to treat the life-threatening symptoms," said co-corresponding author Dr. Robert Schwartz, an associate professor of medicine at Weill Cornell Medicine and a gastroenterologist and hepatologist at NewYork-Presbyterian/Weill Cornell Medical Center. "But moving forward, there may be a way to develop clinical therapeutics that help avoid later injury to organs like the pancreas."

Dr. Liuliu Yang and Dr. Yuling Han, who were postdoctoral fellows in the Department of Surgery at the time of the study, and Dr. Tuo Zhang, an instructor in microbiology and immunology at Weill Cornell Medicine, were co-first authors of the paper.

From the early days of the COVID-19 pandemic, doctors caring for sick patients observed that the virus affected a number of organ systems, including not only the lungs but also the heart, liver, colon and pancreas. For the current work, the researchers started with samples of pancreatic tissue from autopsies of people who had died of COVID-19. They observed that the pancreatic islets, the parts of the pancreas that generate the insulin to regulate blood sugar, were damaged.

They then used an analysis technique called GeoMx to study the samples in more detail. This revealed the presence of immune cells called proinflammatory macrophages in the tissues. The job of these macrophages is to kill off pathogens, but they sometimes cause collateral damage to healthy tissues.

To learn more about this activity, the team used a model system developed in the Chen Lab that has never been used before; pancreatic islet organoids (mini organs) that included both a vascular system and immune cells.

"If we want to use organoids to study how a disease progresses, it's important to be able to include components of the immune system in these models," said Chen. In this case, after infecting the organoids with SARS-CoV-2, they found the macrophages appeared to be killing off the beta cells through a type of cell death called pyroptosis.

The team also used the organoids to study how the pancreas responds to infection with another infectious virus: coxsackievirus B4, which has been implicated in the onset of type 1 diabetes. They found a similar macrophage response.

"Moving forward, this organoid system is going to be useful for looking at other viruses as well," Schwartz said.

Further research on the signaling molecules that activate the macrophages also suggested potential interventions for protecting beta cells from damage in patients with severe infections. Although it is too early to begin testing any treatments, this is something that may be possible in the future. This work could also help shed light on the underlying causes of long COVID, a condition that is believed to affect more than 15 million people in the United States.

More information: Liuliu Yang et al, Human vascularized macrophage-islet organoids to model immune-mediated pancreatic ß cell pyroptosis upon viral infection, Cell Stem Cell (2024). DOI: 10.1016/j.stem.2024.08.007
Journal information: Cell Stem Cell
Provided by Cornell University
 

meandk0610

Veteran Member
(fair use applies)


Dutch study warns that repeated COVID-19 mRNA vaccinations affect immune response in older adults
Sebastian Lavoie Fact checked by:Thailand Medical News Team
Sep 16, 2024

A recent study conducted by researchers at the National Institute for Public Health and the Environment (RIVM) in the Netherlands has shed new light on how repeated COVID-19 mRNA vaccinations affect the immune system of older adults. The study focused on the changes in antibody responses among individuals aged 65 to 83 who received multiple doses of the vaccine. This COVID-19 News report delves into the key findings and explores how the repeated vaccinations may influence immune functions, particularly in older populations.

The study examines the way repeated mRNA vaccines lead to a class switch in antibodies and the subsequent effects on immune functionality. The study team were particularly interested in the shift in antibody types in older adults and how this could impact vaccine efficacy.


Understanding the Immune Response to COVID-19 mRNA Vaccines
Previous research claimed that the COVID-19 mRNA vaccines are highly effective at boosting immunity by stimulating the production of antibodies that target the SARS-CoV-2 spike protein. These antibodies are critical for neutralizing the virus and preventing severe illness. However, as the global vaccine rollout continued, researchers observed that the nature of the antibody response changed with each additional booster dose, particularly in older adults.

In the initial doses, the vaccine primarily induces antibodies belonging to the IgG1 and IgG3 subclasses, which are proficient at neutralizing the virus and activating immune cells such as natural killer (NK) cells. These antibodies are vital for eliminating infected cells and preventing the spread of the virus within the body.


The IgG4 Class Switch and Its Implications
One of the most intriguing findings from the study is the discovery of a class switch from IgG1 and IgG3 to IgG4 after repeated mRNA vaccinations. This class switching refers to the process by which the immune system produces different types of antibodies, each with unique functions. Researchers observed that after the third vaccination, there was a significant increase in IgG4 antibodies, which are less effective at neutralizing viruses and activating immune cells compared to IgG1 and IgG3. The switch to IgG4 is thought to occur because of prolonged exposure to the spike protein, either through infection or repeated vaccinations.

Unlike IgG1 and IgG3, IgG4 has a unique structural property called Fab-arm exchange, which allows it to bind to two different antigens at once, reducing its ability to form strong complexes and trigger immune responses. This change could have profound implications for how well the immune system responds to future exposures to SARS-CoV-2.


Reduced NK Cell Activation and Immune Efficiency
A crucial part of the study focused on the ability of antibodies to activate NK cells, which play a key role in clearing infected cells. The researchers measured

NK cell activation in response to the spike protein in blood samples from older adults after their second, third, and fifth vaccine doses. The results showed a clear decrease in NK cell activation as the proportion of IgG4 antibodies increased. This means that as the immune system produces more IgG4 antibodies, its ability to mount a robust response against the virus may be compromised.

Additionally, researchers found that the efficiency of the complement system - a crucial part of the immune system responsible for marking pathogens for destruction - also decreased with the rise in IgG4 levels. The complement system relies heavily on IgG1 and IgG3 to function effectively, and the shift to IgG4 could impair its ability to fight infections.


Comparing Younger and Older Adults
The study also compared antibody responses between older and younger adults. While both age groups experienced an increase in IgG4 after repeated vaccinations, older adults exhibited a more pronounced shift. This could be due to age-related changes in the immune system, which tend to make older individuals less responsive to vaccines and more susceptible to infections.

Researchers noted that younger adults maintained higher levels of IgG1 and IgG3 even after receiving their third dose of the vaccine. This suggests that their immune systems were better able to preserve the types of antibodies that are most effective at neutralizing the virus and activating immune cells.


Impact on Vaccine Effectiveness
One of the most important questions arising from this study is whether the increase in IgG4 antibodies will affect the overall effectiveness of the COVID-19 mRNA vaccines. The researchers emphasized that IgG4 antibodies are not inherently harmful; in fact, they play a critical role in regulating the immune system and preventing excessive inflammation. However, the reduced capacity of IgG4 to activate NK cells and the complement system raises concerns about whether repeated vaccinations might diminish the body’s ability to clear the virus efficiently.

It’s important to note that the vaccines remain highly effective at preventing severe disease and death, even in older adults who experience this class switch. However, the study's authors suggest that further research is needed to fully understand how the long-term use of mRNA vaccines will influence the immune system, especially in vulnerable populations like the elderly.


Conclusions and Future Research
The findings from this study offer valuable insights into the complex dynamics of the immune response to COVID-19 mRNA vaccines. The class switch from IgG1 and IgG3 to IgG4 highlights the adaptability of the immune system, but it also raises important questions about how this shift affects the body's ability to fight off infections. Additional research is needed to explore the mechanisms behind this class switching and to determine whether alternative vaccination strategies might be more effective for older adults.

In conclusion, repeated COVID-19 mRNA vaccinations in older adults lead to a significant increase in IgG4 antibodies, which are less effective at activating key immune functions. While the vaccines continue to provide strong protection against severe illness, understanding these shifts in immune response is crucial for optimizing future vaccination strategies, especially for vulnerable populations. This study underscores the need for ongoing research to ensure that booster campaigns remain effective as the pandemic evolves.

The study findings were published in the peer-reviewed journal: Immunity & Ageing.

It’s not even that IgG4 is less effective (read: that’s a BS statement in the article so people don’t stop getting injected). IgG4 is most common in children because it actively damps down the immune system so their bodies do t overreact to everything that’s new!
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Use of metformin in adults with diabetes linked to lower risk of long COVID
by National Institutes of Health
September 17, 2024

Adults who use the prescription drug metformin to treat their type 2 diabetes have a lower risk of developing long COVID or dying after a COVID-19 infection than people with diabetes who take other anti-diabetes medications, according to a recent large study. The findings, published in the journal Diabetes Care, were based on health data from millions of U.S. patients and could have broader implications for the use of metformin in long COVID prevention generally.

A clinical trial in 2023 showed that treatment with metformin, commonly used to help control blood sugar, reduced the risk of long COVID by as much as 40% in nearly 1,300 U.S. adults with overweight or obesity, most of whom did not have diabetes. To see whether the drug had a similar effect in people with diabetes, researchers examined electronic health record data for nearly 38 million Americans from two large U.S. databases.

The researchers compared health records from 75,996 adults taking metformin for their type 2 diabetes to 13,336 records from patients who were not taking metformin but were using other types of diabetes medicines. Researchers were specifically looking at how many patients either died or were diagnosed with long COVID within six months after infection. They found that patients taking metformin had a 13% to 21% lower incidence of long COVID or death than those in the non-metformin group.

Scientists are not clear how metformin may prevent long COVID, but they speculate about the possibility of several mechanisms that reduce inflammation, decrease viral levels, and suppress the formation of disease-related proteins.

Metformin can have side effects and should be used with caution in some conditions. For these and other reasons, people should not take the drug unless prescribed by a doctor.

Long COVID is marked by a wide range of symptoms—including chronic fatigue, brain fog, and chest pain—that vary from person to person and can last for weeks, months, or years after infection from SARS-CoV-2, the virus that causes COVID-19. While rates of new cases have decreased since early in the COVID-19 pandemic, millions of people are still living with it.

More information: Johnson SG et al, Prevalent Metformin Use in Adults with Diabetes and the Incidence of Long Covid: An EHR-based Cohort Study from the RECOVER Program, Diabetes Care (2024). DOI: 10.2337/dca24-0032
Journal information: Diabetes Care
Provided by National Institutes of Health
 

Heliobas Disciple

TB Fanatic
(fair use applies)


COVID-19 rates oscillate every six months in the US, new study shows
by University of Pittsburgh
September 17, 2024

COVID-19 cases in the U.S. have shown unexpected oscillating waves every six months between the southern states and the northern states and, to a lesser degree, from east to west, according to research published in Scientific Reports.

Public health scientists from the University of Pittsburgh, University of Ottawa and University of Washington conducted the first detailed analysis to demonstrate and characterize the six-month oscillation of cases across space and time. It provides key information that could inform public health activities, such as vaccination campaigns, that aim to control the virus.

"The COVID-19 winter waves are consistent with that of other respiratory viruses, but the existence of a repeated additional surge during the summer was unexpected," said senior author Donald S. Burke, M.D., dean emeritus of Pitt's School of Public Health.

"These waves start near the southern U.S. border in July and August, when the weather is hottest and the humidity is high—factors that usually tamp down the spread of respiratory viruses. We don't have a good explanation for why COVID-19 rates should increase in both the warmest and coolest times of the year."

The research team, which includes lead author Hawre Jalal, M.D., Ph.D., of the University of Ottawa, and Kyueun Lee, Ph.D., of the University of Washington, believe the data suggest the six-month U.S. COVID-19 waves may be part of a larger pattern sweeping up and down the North American continent.

Further data is needed to test the hypothesis and determine the exact mechanisms fueling these unexpected seasonal oscillations.

More information: Hawre Jalal et al, Oscillating spatiotemporal patterns of COVID-19 in the United States, Scientific Reports (2024). DOI: 10.1038/s41598-024-72517-6
Journal information: Scientific Reports
Provided by University of Pittsburgh
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Exclusive: Study Finds COVID Harmed Cognitive Skills of Students — and Teachers
Greg Toppo - The 74
Wed, September 18, 2024 at 10:30 AM UTC

New research may help educators and families zero in on exactly how the COVID-19 pandemic caused such an unprecedented academic slump, suggesting that the culprit lies in something basic and crucial: children’s ability to think, remember and problem-solve.

And here’s a twist: The same core difficulties are bedeviling teachers too.

The findings, contained in a new working paper, are believed to be the first to identify brain changes as an explanation for why students have suffered, both inside and outside the classroom, since the pandemic drove millions out of the classroom.

Nancy Tsai, a Harvard University psychologist who studies the effects of stress on executive functions and who is the study’s lead author, said the new findings offer the first evidence to help us “understand the ‘why’” of the pandemic downturn — “what is actually causing all these issues that we’re seeing and talking about in the news.”

The paper, from the private tutoring firm MindPrint Learning, examines the cognitive skills of students nationwide and finds that, simply put, over the past several years, kids’ famously ever-changing brains have changed for the worse.

Since the pandemic’s onset, students across all ages and economic levels have begun to demonstrate weaker memory and “flexible thinking” skills — those represent the mental bandwidth needed for multitasking, shifting from one activity to another and juggling the day’s demands. But for a few groups, such as younger and lower-income children, the changes have been more profound.

They also show that their teachers’ brains are weaker in almost identical ways, which could help explain high rates of frustration and burnout. They suggest school districts have their work cut out for them if they want to keep their best employees on the payroll and returning to the classroom each fall.


Understanding the ‘why’ of pandemic downturn

The data come from a large, widely-used assessment, the Penn Computerized Neurocognitive Battery, developed in 2013 at the University of Pennsylvania. It consists of a series of cognitive tasks that measure subjects’ accuracy and speed in several major cognitive domains, including working memory, abstraction, sustained attention, episodic memory and processing speed.

MindPrint has administered the assessment periodically to its clients over the past decade. The most recent rounds totaled 35,000 students and 4,000 teachers in 27 states.


Why America Is Lagging Behind in Catching Students Up After COVID

By most measures, U.S. students are suffering. Last year, NAEP scores showed the average 13-year-old’s understanding of math dropping to levels last seen in the 1990s and reading levels dropping to 1971, when the test was first administered.

More recent research has shown that while older children are showing encouraging signs of academic recovery, younger kids aren’t making the same progress. Many students who weren’t even in a formal school setting when COVID hit are already falling behind — especially in math.

The Penn assessment found that children who attended elementary or pre-school during the pandemic and who are now 8 to13 years old showed the largest declines in memory.

“Younger kids haven’t really developed a lot of these core cognitive skills,” Tsai said. “It hasn’t solidified for them, either through development or just through practice in the classroom. And so younger kids are more vulnerable to these pandemic shifts.”

But students across all age groups showed worse flexible thinking, which researchers now theorize contributes to lower academic performance — as well as challenging behaviors.

Tsai said kids from lower income backgrounds were more vulnerable to these changes, specifically in verbal reasoning and verbal memory, than their higher income peers, with bigger declines in verbal scores, which are highly correlated with academic achievement in all subjects.

Adults in the study had similar declines in both memory and flexible thinking, possibly explaining higher reported levels of teacher dissatisfaction and low morale.


‘Education’s Long COVID’: New Data Shows Recovery Stalled for Most Students


Nancy Weinstein, MindPrint’s CEO, said weaker flexible thinking isn’t necessarily a problem for experienced teachers who have developed strategies to cope with stressful situations and can modify plans on the fly. But those with less experience may be unable to change gears when lessons go astray or students act out in class. That may lead to higher teacher burnout.

Across the board, teachers’ skills suffered in areas such as verbal and abstract reasoning, spatial perception, attention and working memory, but they saw the greatest losses in verbal memory and flexible thinking.

“If we care about that, we need to know how to help them,” Weinstein said. “And there are some tried and true things you can do.”

She said schools should consider sharing data like this with teachers so they can understand that their frustration in class might not be due to students alone. That could make a big difference, she said, in “their willingness to put in the effort to change, as opposed to saying, ‘Why bother?’”


Students Headed to High School Are Academically a Year Behind, COVID Study Finds

For students, Weinstein said, offering them more opportunities to practice skills with breaks and rest between study sessions could help. Schools should also consider “scaffolded memorization” techniques that break learning into chunks and address each individually.

Could such techniques help students — and teachers — regain a measure of pre-pandemic skills? Weinstein suggests the answer is “Yes.”

“The environment will matter, but certainly we can regain some of that if we do the right things,” she said. “And we know what the right things are to do.”

Crystal Green-Braswell, coordinator of staff wellness and culture for the Little Rock School District in Arkansas, said offering the Penn assessment to teachers and staff has helped many think more deeply about their work — and about their own thinking.

“People who have had the assessment will say, ‘Now, you know my processing speed is slower — y’all are going to have to give me a moment,’” she said.

That’s a huge change in a profession in which most workers have been asked “to take ourselves out of the equation and just get the work done,” Green-Braswell said.

She sees offering such insights to educators as part of “rehumanizing” teaching. “When we provide this kind of assessment and we provide this kind of space for folks to actually get to know themselves, we are humanizing this profession and helping people to realize, ‘You play a role. You play an active role. You matter.’ ”
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Antiviral-resistant variants of SARS-CoV-2 can emerge in immunocompromised people

by Weill Cornell Medical College
September 18, 2024


antiviral-resistant-va.jpg

Structural analysis of nsp5 T169I and nsp12 V792I substitutions. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-51924-3

Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 virus, which have the potential to spread to the general population found researchers at Weill Cornell Medicine, the College of Veterinary Medicine at Cornell University and the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID).

In the study, published Sept. 18 in Nature Communications, researchers isolated drug-resistant strains of SARS-CoV-2 from people who had not cleared the virus after two to three months of infection and treatments with antiviral drugs.

One variant showed resistance to antivirals Paxlovid and remdesivir while another strain had mutations associated with a decreased sensitivity to remdesivir and a third antiviral drug, the monoclonal antibody sotrovimab.

"The risk in emerging mutations is the possibility of transmitting these new resistant variants to the general population with fewer viable treatment options available," said the study's co-senior author, Dr. Mirella Salvatore, associate professor of medicine at Weill Cornell Medicine and infectious disease physician at NewYork-Presbyterian/Weill Cornell Medical Center. "We have to come up with better treatments for immunocompromised patients and consider investigating combinations of therapies."

Dr. Elodie Ghedin, senior investigator and chief of the Systems Genomics Section in NIAID, is co-senior author. Dr. Mohammed Nooruzzaman, research associate in the Diel Lab at the College of Veterinary Medicine at Cornell University, and Katherine Johnson, senior bioanalyst contractor in NIAID, are co-first authors.


Unique challenges in treating persistent COVID infections


While people with working immune systems can typically clear SARS-CoV-2 within days, those who are immunocompromised may continue to harbor and shed the virus for longer, even without symptoms. They also often receive multiple antiviral treatments over time, which may lead to the emergence of drug-resistant variants.

To understand the rise of antiviral drug resistance, the researchers focused on 15 individuals with compromised immune systems who received remdesivir, and in some cases, nirmatrelvir-ritonavir (Paxlovid). They found nine patients had developed virus variants with mutations to the nsp12 protein that is the target of remdesivir and four had viruses with mutations to the nsp5 protein, the target of Paxlovid. These mutations helped the virus persist despite common antiviral treatments.

One person had a virus resistant to both drugs. "For the first time, we isolated virus from a patient's nose 77 days after disease onset that was resistant to Paxlovid and also to remdesivir," Dr. Salvatore said. "It is concerning that some of these patients may have viable virus in their nasal secretions so far into the disease."


Combination therapies may be the answer

The researchers found that when they grew the isolated virus in lab cell cultures, two drugs simultaneously were effective in clearing the drug-resistant strain. "These findings indicate that combination therapy may be a better option to treat COVID-19 in highly vulnerable immunocompromised patients," said co-senior author Dr. Diego Diel, associate professor of population medicine and diagnostic sciences with the College of Veterinary Medicine at Cornell University.

The researchers also found that the resistant strain replicated as well as the original SARS-CoV-2 virus in cell culture. Next, using a preclinical model, they tested whether the virus could spread through contact. They discovered this variant was as transmissible as the wildtype virus without the mutations.

It is generally assumed that when a virus acquires drug-resistance mutations, it loses some of its fitness, meaning it may not replicate or transmit from person to person as well—this study shows that isn't the case. The authors will further investigate how mutations associated with therapeutics impact the virus's ability to thrive and spread.

This research highlights the importance of including cohorts of immunocompromised COVID-19 patients when evaluating the efficacy of antivirals. "When the virus has more time to evolve in a host who does not clear the infection early, therapeutic strategies will need to be reassessed," said the authors.

More information: Nooruzzaman, M. Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections, Nature Communications (2024). DOI: 10.1038/s41467-024-51924-3
Journal information: Nature Communications
Provided by Weill Cornell Medical College
 

Heliobas Disciple

TB Fanatic
Not endorsing this article, posting it because it's in the news cycle and some folks still believe it..... (you'd think they'd give it up by now but I guess not!)



(fair use applies)


A new genetic analysis of animals in the Wuhan market in 2019 may help find COVID-19's origin
Maria Cheng
Updated Thu, September 19, 2024, 8:25 PM EDT

LONDON (AP) — Scientists searching for the origins of COVID-19 have zeroed in on a short list of animals that possibly helped spread it to people, an effort they hope could allow them to trace the outbreak back to its source.

Researchers analyzed genetic material gathered from the Chinese market where the first outbreak was detected and found that the most likely animals were racoon dogs, civet cats and bamboo rats. The scientists suspect infected animals were first brought to the Wuhan market in late November 2019, which then triggered the pandemic.

Michael Worobey, one of the new study’s authors, said they found which sub-populations of animals might have transmitted the coronavirus to humans. That may help researchers pinpoint where the virus commonly circulates in animals, known as its natural reservoir.

“For example, with the racoon dogs, we can show that the racoon dogs that were (at the market) … were from a sub-species that circulates more in southern parts of China,” said Worobey, an evolutionary biologist at the University of Arizona. Knowing that might help researchers understand where those animals came from and where they were sold. Scientists might then start sampling bats in the area, which are known to be the natural reservoirs of related coronaviruses like SARS.

While the research bolsters the case that COVID-19 emerged from animals, it does not resolve the polarized and political debate over whether the virus instead emerged from a research lab in China.

Mark Woolhouse, a professor of infectious diseases at the University of Edinburgh, said the new genetic analysis suggested that the pandemic “had its evolutionary roots in the market” and that it was very unlikely COVID-19 was infecting people before it was identified at the Huanan market.

“It’s a significant finding and this does shift the dial more in favor of an animal origin," Woolhouse, who was not connected to the research, said. “But it is not conclusive.”

An expert group led by the World Health Organization concluded in 2021 that the virus probably spread to humans from animals and that a lab leak was “extremely unlikely.” WHO chief Tedros Adhanom Ghebreyesus later said it was “premature” to rule out a lab leak.

An AP investigation in April found the search for the COVID origins in China has gone dark after political infighting and missed opportunities by local and global health officials to narrow the possibilities.

Scientists say they may never know for sure where exactly the virus came from.

In the new study, published Thursday in the journal Cell, scientists from Europe, the U.S. and Australia analyzed data previously released by experts at the Chinese Center for Disease Control and Prevention. It included 800 samples of genetic material Chinese workers collected on Jan. 1, 2020 from the Huanan seafood market, the day after Wuhan municipal authorities first raised the alarm about an unknown respiratory virus.

Chinese scientists published the genetic sequences they found last year, but did not identify any of the animals possibly infected with the coronavirus. In the new analysis, researchers used a technique that can identify specific organisms from any mixture of genetic material collected in the environment.

Worobey said the information provides “a snapshot of what was (at the market) before the pandemic began” and that genetic analyses like theirs “helps to fill in the blanks of how the virus might have first started spreading.”

Woolhouse said the new study, while significant, left some critical issues unanswered.

“There is no question COVID was circulating at that market, which was full of animals,” he said. “The question that still remains is how it got there in the first place.”
 

Heliobas Disciple

TB Fanatic
(fair use applies)


New XEC COVID Variant Identified in Some States—What to Know About Symptoms, Transmission
Maggie O'Neill - Health
Thu, September 19, 2024, 12:00 PM EDT

  • The XEC COVID variant spread rapidly in Denmark, Germany, and the Netherlands over the summer, and it has now been reported in New York, California, and some other U.S. states.
  • But experts said there’s no evidence to suggest it causes any new symptoms or more severe disease.
  • The updated COVID vaccines should still offer strong protection against hospitalization, severe disease, and death, experts said.

American infectious disease experts are now tracking a new COVID variant called XEC, which has made waves in Europe and is already spreading in the U.S.

The new variant is making headlines, as many experts speculate it could become the next predominant variant in the U.S. over the coming months.

Eric Topol, MD, executive vice president of Scripps Research, wrote on X that XEC “appears to be the most likely one to get legs next.”

The variant spread rapidly in Germany, Denmark, and the Netherlands over the summer, and there have now been cases of XEC reported in the U.S., Thomas Russo, MD, professor and chief of infectious disease at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, told Health.

However, XEC has not yet been featured in the variant surveillance data from the Centers for Disease Control and Prevention (CDC), which could be because the U.S. hasn’t seen enough cases of it yet.

“If it’s [responsible for] less than 1% [of cases], it doesn’t make the CDC surveillance chart,” Russo explained.

Even though infectious disease experts are preemptively warning people about XEC, in general, concern is still relatively low.

There’s a good chance that XEC is “quite contagious,” William Schaffner, MD, professor of medicine in the division of infectious diseases at Vanderbilt University Medical Center, told Health. But, he explained, “just because it’s new, doesn’t mean it creates any more worries than our current variants.”

Here’s what experts want you need to know about the XEC variant—including how it compares to existing variants and what to do to stay safe this fall and winter.


The Status of XEC in the U.S. Right Now

The XEC variant seems to be “more of the same,” said Schaffner. However, the possibility of its rise in the U.S. is being monitored.

According to CDC data from mid-September, KP.3.1.1 was the most dominant variant, followed by KP.2.3 and LB.1. But XEC had been reported in a handful of states—including South Dakota, Washington, Maryland, and California—as of the beginning of September.

XEC is yet another Omicron variant—more specifically, it’s related to KP.3.3, which itself is a descendant of the “FLiRT” variants that fueled a spike in cases over the summer.

“We had a considerable increase [in COVID cases] this summer,” Schaffner said. “The increase has been a bit higher, lasted a bit longer” than anticipated.

Coming off of this summer surge, it’s unclear how XEC might shape the upcoming respiratory virus season in the U.S. Though the variant spread rapidly in some European countries, experts said it will take time to sort out whether XEC is really more infectious than these previous strains.

But experts do think that the new COVID vaccines—now available in the U.S.—will offer protection against the XEC variant. “Very early laboratory” reports suggest that this is the case since XEC is in the Omicron family, said Schaffner.

The protection may be slightly less effective against the XEC variant as compared to previously-circulating variants the vaccines were specifically designed to protect against, Russo explained. However, he said, “the likelihood that the vaccine is going to help prevent severe disease, hospitalization, and death is quite high.”


Are There Any New Symptoms Associated with the XEC Variant?


Unfortunately, if you’re feeling sick, you probably won’t be able to tell if you’ve come down with XEC or a different COVID strain. For now, there doesn’t seem to be any distinct or unique symptoms associated with the new variant, Russo and Schaffner agreed.

That said, people infected with XEC could experience any of the following known COVID symptoms:
  • Fever or chills
  • Congestion
  • Runny nose
  • Cough
  • Loss of taste or smell
  • Shortness of breath
  • Body aches
  • Sore throat
  • Fatigue
  • Nausea
  • Vomiting
  • Headache
  • Diarrhea
If you ever experience trouble breathing, confusion, pain or pressure in your chest, or difficulty staying awake, that could be a sign of an emergency, and you should seek medical care immediately.

If you test positive for COVID, it’s as important as it always has been to stay away from others to protect vulnerable people in your community, experts said. You should also consider whether the antiviral Paxlovid could help you—particularly if you’re at high risk for severe disease—and should start taking the medication sooner rather than later if your doctor recommends it, Russo explained.

But again, since there’s no evidence suggesting the XEC variant will behave in a significantly different way than previous variants, people shouldn’t necessarily be too concerned about its spread.

“The evolution of this virus is going to continue in perpetuity,” Amesh Adalja, MD, a biosecurity and emerging infectious diseases expert at the Johns Hopkins Bloomberg School of Public Health, told Health. “One [variant] is always going to be rising, one is going to be falling—that’s what respiratory viruses do.”
 

jward

passin' thru

dstraito

TB Fanatic
Just an observation

Today at a sonogram of the heart,I asked the technician

How are you?

Busy.

Have you seen an increase in the normal number of people you treat?

Yes.

Do you have an idea as to why?

Yes.

I have an idea that the vax caused this.

Yes.

I guess you have to watch what you say.

Yes.

She said "You have no idea of the doctors that tried to voice their opinion"

I said "They had to be careful or they would be sanctioned?"

Yes.

I said "I have heard there are a lot more cases of myocarditis"

She said "Yes. especially among younger people"

I said "I did not take the shot"

She said "I did not either"



I got the idea she was skirting a careful line of what she could and could not say but it reaffirmed in me that I made the right decision.
 
Top